

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification 5 : <b>C12N 15/54, 15/62, 15/10, 15/63, 9/10</b></p>		A1	<p>(11) International Publication Number: <b>WO 94/12646</b></p> <p>(43) International Publication Date: <b>9 June 1994 (09.06.94)</b></p>
<p>(21) International Application Number: <b>PCT/EP93/03194</b></p> <p>(22) International Filing Date: <b>15 November 1993 (15.11.93)</b></p> <p><b>(30) Priority Data:</b> 92810924.8 27 November 1992 (27.11.92) EP (34) Countries for which the regional or international application was filed: DE et al.</p>		<p>(81) Designated States: AU, CA, FI, JP, KR, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p><b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(71) Applicant (for all designated States except US): CIBA-GEIGY AG [CH/CH]; Klybeckstrasse 141, CH-4002 Basle (CH).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): BERGER, Eric, G. [CH/CH]; Zum Müliweiher 4, CH-8165 Schöftisdorf (CH). WATZEL, Manfred [DE/DE]; Ringstrasse 2, D-82362 Weilheim (DE). IWANOW, Svetoslav, X. [BG/BG]; ul. "Ivan Assen 2" Nr. 37, Sofia 1504 (BG).</p> <p>(74) Common Representative: CIBA-GEIGY AG; Patentabteilung, Klybeckstrasse 141, CH-4002 Basle (CH).</p>			
<p><b>(54) Title:</b> PROTEINS HAVING GLYCOSYLTRANSFERASE ACTIVITY</p> <p><b>(57) Abstract</b></p> <p>The invention concerns proteins having glycosyltransferase activity, recombinant DNA molecules encoding proteins having glycosyltransferase activity, hybrid vectors comprising such recombinant DNA molecules, transformed hosts suitable for the multiplication and/or expression of the recombinant DNA molecules, and processes for the preparation of the proteins, DNA molecules and hosts.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Proteins having glycosyltransferase activity

The invention relates to proteins having glycosyltransferase activity and to a recombinant process for the production of proteins having glycosyltransferase activity.

Glycosyltransferases transfer sugar residues from an activated donor substrate, usually a nucleotide sugar, to a specific acceptor sugar thus forming a glycosidic linkage. Based on the type of sugar transferred, these enzymes are grouped into families, e.g. galactosyltransferases, sialyltransferases and fucosyltransferases. Being resident membrane proteins primarily located in the Golgi apparatus, the glycosyltransferases share a common domain structure consisting of a short amino-terminal cytoplasmic tail, a signal-anchor domain, and an extended stem region which is followed by a large carboxy-terminal catalytic domain. The signal-anchor or membrane domain acts as both uncleavable signal peptide and as membrane spanning region and orients the catalytic domain of the glycosyltransferase within the lumen of the Golgi apparatus. The luminal stem or spacer region is supposed to serve as a flexible tether, allowing the catalytic domain to glycosylate carbohydrate groups of membrane-bound and soluble proteins of the secretory pathway enroute through the Golgi apparatus. Furthermore, the stem portion was discovered to function as retention signal to keep the enzyme bound to the Golgi membrane (PCT Application No. 91/06635). Soluble forms of glycosyltransferases are found in milk, serum and other body fluids. These soluble glycosyltransferases are supposed to result from proteolytic release from the corresponding membrane-bound forms of the enzymes by endogenous proteases.

Glycosyltransferases are valuable tools for the synthesis or modification of glycoproteins, glycolipids and oligosaccharides. Enzymatic synthesis of carbohydrate structures has the advantage of high stereo- and regioselectivity. In contrast to chemical methods the time-consuming introduction of protective groups is superfluous. However, enzymatic synthesis of carbohydrate structures has been a problem because glycosyltransferases are not readily available. Therefore, production using recombinant DNA technology has been worked on. For example, galactosyltransferases have been expressed in *E. coli* (PCT 90/07000) and Chinese hamster ovary (CHO) cells (Smith, D.F. et al. (1990) *J. Biol. Chem.* 265, 6225-34), sialyltransferases have been expressed in CHO cells (Lee, E.U. (1990) *Diss. Abstr. Int. B.50, 3453-4*) and COS-1 cells (Paulson, J.C. et al. (1988) *J. Cell.*

- 2 -

Biol. 107, 10A), and fucosyltransferases have been produced in COS-1 cells (Goetz, S.E. et al. (1990) Cell 63, 1349-1356; Larsen R.D. et al. (1990) Proc. Natl. Acad. Sci. USA 87, 6674-6678) and CHO cells (Potvin, B. (1990) J. Biol. Chem. 265, 1615-1622). Recently, Paulson et al. have disclosed a method for producing soluble glycosyltransferases (U.S. Patent No. 5,032,519). However, there still is a need for proteins having favorable glycosylating properties and for advantageous methods for producing such proteins.

It is an object of the present invention to provide novel proteins having glycosyltransferase activity, recombinant DNA molecules encoding proteins having glycosyltransferase activity, hybrid vectors comprising such recombinant DNA molecules, transformed hosts suitable for the multiplication and/or expression of the recombinant DNA molecules, and processes for the preparation of the proteins, DNA molecules and hosts.

The present invention concerns a protein having glycosyltransferase activity and comprising identical or different catalytically active domains of glycosyltransferases, e.g. hybrid proteins.

Preferred is a protein of the invention which comprises two identical or two different catalytically active domains of glycosyltransferases.

Particularly preferred is such a protein exhibiting two different glycosyltransferase activities, i.e. a protein capable of transferring two different sugar residues.

Besides the catalytically active domains a protein of the invention may comprise additional amino acid sequences, particularly amino acid sequences of the respective glycosyltransferases.

The invention also concerns a hybrid polypeptide chain, i.e. a hybrid protein, comprising a membrane-bound or soluble glycosyltransferase linked to a soluble glycosyltransferase. For example, such a hybrid protein comprises a membrane-bound glycosyltransferase linked to a soluble glycosyltransferase in N-to C-terminal order.

A glycosyltransferase is a protein exhibiting glycosyltransferase activity, i.e. transferring a particular sugar residue from a donor molecule to an acceptor molecule. Examples are N-acetylglucosaminyltransferases, N-acetylgalactosaminyltransferases, mannosyltransferases, fucosyltransferases, galactosyltransferases and sialyltransferases.

Preferably, the glycosyltransferase is of mammalian, e.g. bovine, murine, rat or, particularly, human origin.

Preferred are hybrid proteins exhibiting galactosyl- and sialyltransferase activity.

A membrane-bound glycosyltransferase is an enzyme which cannot be secreted by the cell it is produced by, e.g. a full-length enzyme. Examples of membrane-bound glycosyltransferases are the following galactosyltransferases: UDP-Galactose:  $\beta$ -galactoside  $\alpha$ (1-3)-galactosyltransferase (EC 2.4.1.151) which uses galactose as acceptor substrate forming an  $\alpha$ (1-3)-linkage and UDP-Galactose:  $\beta$ -N-acetylglucosamine  $\beta$ (1-4)-galactosyltransferase (EC 2.4.1.22) which transfers galactose to N-acetylglucosamine (GlcNAc) forming a  $\beta$ (1-4)-linkage. In the presence of  $\alpha$ -lactalbumin, said  $\beta$ (1-4)-galactosyltransferase also accepts glucose as an acceptor substrate, thus catalysing the synthesis of lactose. An example of a membrane-bound sialyltransferase is the CMP-NeuAc:  $\beta$ -galactoside  $\alpha$ (2-6)-sialyltransferase (EC 2.4.99.1) which forms the NeuAc- $\alpha$ (2-6)Gal- $\beta$ (1-4)GlcNAc-sequence common to many N-linked carbohydrate groups.

A soluble glycosyltransferase is secretable by the host cell and is derivable from an N-terminally truncated full-length (i.e. a membrane-bound) glycosyltransferase naturally located in the Golgi apparatus. Such a soluble glycosyltransferase differs from the corresponding full-length enzyme by lack of the cytoplasmic tail, the signal anchor and, optionally, part or whole of the stem region. An example of soluble glycosyltransferases are galactosyltransferases differing from the protein with the amino acid sequence depicted in SEQ ID NO. 1 in that they lack an NH<sub>2</sub>-terminal peptide comprising at least 41 amino acids. A soluble sialyltransferase is e.g. a sialyltransferase missing an NH<sub>2</sub>-terminal peptide consisting of 26 to 61 amino acids as compared to the full length form depicted in SEQ ID No. 3.

As used hereinbefore and hereinafter the term "glycosyltransferase" is intended to include variants with the provision that these variants are enzymatically active. Preferred are variants of human origin.

For example, a variant is a naturally occurring variant of a glycosyltransferase found within a particular species, e.g. a variant of a galactosyltransferase which differs from the enzyme having the amino acid sequence with the SEQ ID NO. 1 in that it lacks serine in

position 11 and has the amino acids valine and tyrosine instead of alanine and leucine in positions 31 and 32, respectively. Such a variant may be encoded by a related gene of the same gene family or by an allelic variant of a particular gene. The term "variant" also embraces a modified glycosyltransferase, e.g. a glycosyltransferase produced from a DNA which has been subjected to in vitro mutagenesis, with the provision that the protein encoded by said DNA has the enzymatic activity of the authentic glycosyltransferase. Such modifications may consist in an addition, exchange and/or deletion of one or more amino acids, the latter resulting in shortened variants. An example of a shortened membrane-bound, catalytically active variant is the galactosyltransferase designated GT<sub>(1-396)</sub> consisting of amino acids 1 to 396 of the amino acid sequence depicted in SEQ ID No. 1.

Preferred hybrid proteins comprise a membrane-bound or soluble glycosyltransferase linked to a soluble glycosyltransferase molecule, or a variant thereof, via a suitable linker consisting of genetically encoded amino acids. A suitable linker is a molecule which does not impair the favorable properties of the hybrid protein of the invention. The linker connects the C-terminal amino acid of one glycosyltransferase molecule with the N-terminal amino acid of the another glycosyltransferase molecule. For example, the linker is a peptide consisting of about 1 to about 20, e.g. of about 8 amino acids. In a preferred embodiment the linker, also referred to as adaptor, does not contain the amino acid cysteine. Particularly preferred is a peptide linker having the sequence Arg-Ala-Arg-Ile-Arg-Arg-Pro-Ala or Arg-Ala-Gly-Ile-Arg-Arg-Pro-Ala.

Preferred is a hybrid protein consisting of a galactosyltransferase linked to a sialyltransferase via a suitable peptide linker.

Particularly preferred is a hybrid protein consisting of a membrane-bound galactosyltransferase the C-terminal amino acid of which is linked to the N-terminal amino acid of a soluble sialyltransferase via a suitable peptide linker, e.g. a hybrid protein having the amino acid sequence set forth in SEQ ID NO. 6 or in SEQ ID NO. 8.

The hybrid protein according to the invention can be prepared by recombinant DNA techniques comprising culturing a suitable transformed yeast strain under conditions which allow the expression of the DNA encoding said hybrid protein. Subsequently, the enzymatic activity may be recovered.

In a preferred embodiment, the desired compounds are manufactured in a process comprising

- a) providing an expression vector comprising an expression cassette containing a DNA sequence coding for a hybrid protein,
- b) transferring the expression vector into a suitable yeast strain,
- c) culturing the transformed yeast strain under conditions which allow expression of the hybrid protein, and
- d) recovering the enzymatic activity.

The steps involved in the preparation of the hybrid proteins by means of recombinant techniques will be discussed in more detail hereinbelow.

The invention further relates to a recombinant DNA molecule encoding a hybrid protein of the invention. Preferred are DNA molecules coding for the preferred hybrid proteins.

The nucleotide sequence encoding a particular glycosyltransferase is known from the literature or can be deduced from the amino acid sequence of the protein according to conventional rules. Starting from the nucleotide sequences encoding the desired glycosyltransferase activities, a DNA molecule encoding the desired hybrid protein can be deduced and constructed according to methods well known in the art including, but not limited to, the use of polymerase chain reaction (PCR) technology, DNA restriction enzymes, synthetic oligonucleotides, DNA ligases and DNA amplification techniques. Alternatively, the nucleotide sequence encoding the hybrid protein of the invention may be synthesized by chemical methods known in the art or by combining chemical with recombinant methods.

The DNA coding for a particular glycosyltransferase may be obtained from cell sources by conventional methods, e.g. by making use of cDNA technology, from vectors in the art or by chemical synthesis of the DNA.

More specifically, DNA encoding a membrane-bound glycosyltransferase can be prepared by methods known in the art and includes genomic DNA, e.g. DNA isolated from a

mammalian genomic DNA library, e.g. from rat, murine, bovine or human cells. If necessary, the introns occurring in genomic DNA encoding the enzyme are deleted. Furthermore, DNA encoding a membrane-bound glycosyltransferase comprises cDNA which can be isolated from a mammalian cDNA library or produced from the corresponding mRNA. The cDNA library may be derived from cells from different tissues, e.g. placenta cells or liver cells. The preparation of cDNA via the mRNA route is achieved using conventional methods such as the polymerase chain reaction (PCR).

A DNA encoding a soluble glycosyltransferase is obtainable from a naturally occurring genomic DNA or a cDNA according to methods known in the art. For example, the partial DNA coding for a soluble form of a glycosyltransferase may be excised from the full-length DNA coding for the corresponding membrane-bound glycosyltransferase by using restriction enzymes. The availability of an appropriate restriction site is advantageous therefor.

Furthermore, DNA encoding a glycosyltransferase can be enzymatically or chemically synthesized.

A variant of a glycosyltransferase having enzymatic activity and an amino acid sequence in which one or more amino acids are deleted (DNA fragments) and/or exchanged with one or more other amino acids, is encoded by a mutant DNA. Furthermore, a mutant DNA is intended to include a silent mutant wherein one or more nucleotides are replaced with other nucleotides, the new codons coding for the same amino acid(s). Such a mutant sequence is also a degenerated DNA sequence. Degenerated DNA sequences are degenerated within the meaning of the genetic code in that an unlimited number of nucleotides are replaced by other nucleotides without resulting in a change of the amino acid sequence originally encoded. Such degenerated DNA sequences may be useful due to their different restriction sites and/or frequency of particular codons which are preferred by the specific host to obtain optimal expression of a glycosyltransferase. Preferably, such DNA sequences have the yeast preferred codon usage.

A mutant DNA is obtainable by in vitro mutation of a cDNA or of a naturally occurring genomic DNA according to methods known in the art.

The invention also concerns hybrid vectors comprising a DNA sequence encoding a hybrid protein of the invention. The hybrid vectors of the invention provide for replication

and, optionally, expression of the DNA encoding a hybrid protein of the invention. A hybrid vector of the invention comprises a DNA sequence encoding a hybrid protein of the invention linked with an origin of replication allowing the replication of the vector in the host cell, or a functionally equivalent sequence. A vector suitable for the expression of the hybrid protein of the invention (an expression vector) comprises a DNA sequence encoding said hybrid protein operably linked with expression control sequences, e.g. promoters, which ensure the effective expression of the hybrid proteins in yeast, and an origin of replication allowing the replication of the vector in the host cell, or a functionally equivalent sequence.

Vectors suitable for replication and expression in yeast contain a yeast replication origin. Hybrid vectors that contain a yeast replication origin, for example the chromosomal autonomously replicating segment (ars), are retained extrachromosomally within the yeast cell after transformation and are replicated autonomously during mitosis. Also, hybrid vectors that contain sequences homologous to the yeast  $2\mu$  plasmid DNA can be used. Such hybrid vectors are integrated by recombination in  $2\mu$  plasmids already present within the cell, or replicate autonomously.

Preferably, the hybrid vectors according to the invention include one or more, especially one or two, selective genetic markers for yeast and such a marker and an origin of replication for a bacterial host, especially Escherichia coli.

As to the selective gene markers for yeast, any marker gene can be used which facilitates the selection for transformants due to the phenotypic expression of the marker gene. Suitable markers for yeast are, for example, those expressing antibiotic resistance or, in the case of auxotrophic yeast mutants, genes which complement host lesions. Corresponding genes confer, for example, resistance to the antibiotics G418, hygromycin or bleomycin or provide for prototrophy in an auxotrophic yeast mutant, for example the URA3, LEU2, LYS2 or TRP1 gene.

As the amplification of the hybrid vectors is conveniently done in E. coli, an E. coli genetic marker and an E. coli replication origin are included advantageously. These can be obtained from E. coli plasmids, such as pBR322 or a pUC plasmid, for example pUC18 or pUC19, which contain both E. coli replication origin and E. coli genetic marker conferring resistance to antibiotics, such as ampicillin.

An expression vector according to the invention comprises an expression cassette comprising a yeast promoter and a DNA sequence coding for hybrid protein of the invention, which DNA sequence is controlled by said promoter.

In a first embodiment, an expression vector according to the invention comprises an expression cassette comprising a yeast promoter, a DNA sequence coding for a hybrid protein, which DNA sequence is controlled by said promoter, and a DNA sequence containing yeast transcription termination signals.

In a second embodiment, the an expression vector according to the invention comprises an expression cassette comprising a yeast promoter operably linked to a first DNA sequence encoding a signal peptide linked in the proper reading frame to a second DNA sequence encoding a hybrid protein, and a DNA sequence containing yeast transcription termination signals.

The yeast promoter may be a regulated or a constitutive promoter preferably derived from a highly expressed yeast gene, especially a Saccharomyces cerevisiae gene. Thus, the promoter of the TRP1 gene, the ADH1 or ADH2 gene, the acid phosphatase (PH05) gene, a promoter of the yeast mating pheromone genes coding for the  $\alpha$ - or  $\alpha$ -factor or a promoter derived from a gene encoding a glycolytic enzyme such as the promoter of the enolase, glyceraldehyde-3-phosphate dehydrogenase (GAP), 3-phosphoglycerate kinase (PGK), hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase or glucokinase genes can be used. Furthermore, it is possible to use hybrid promoters comprising upstream activation sequences (UAS) of one yeast gene and downstream promoter elements including a functional TATA box of another yeast gene, for example a hybrid promoter including the UAS(s) of the yeast PH05 gene and downstream promoter elements including a functional TATA box of the yeast GAP gene (PH05 - GAP hybrid promoter). Preferred is the PH05 promoter, e.g. a constitutive PH05 promoter such as a shortened acid phosphatase PH05 promoter devoid of the upstream regulatory elements (UAS). Particularly preferred is the PH05 (-173) promoter element starting at nucleotide -173 and ending at nucleotide -9 of the PH05 gene.

The DNA sequence encoding a signal peptide ("signal sequence") is preferably derived from a yeast gene coding for a polypeptide which is ordinarily secreted. Other signal sequences of heterologous proteins, which are ordinarily secreted can also be chosen.

Yeast signal sequences are, for example, the signal and prepro sequences of the yeast invertase,  $\alpha$ -factor, pheromone peptidase (KEX1), "killer toxin" and repressible acid phosphatase (PH05) genes and the glucoamylase signal sequence from Aspergillus awamori. Alternatively, fused signal sequences may be constructed by ligating part of the signal sequence (if present) of the gene naturally linked to the promoter used (for example PH05), with part of the signal sequence of another heterologous protein. Those combinations are favoured which allow a precise cleavage between the signal sequence and the glycosyltransferase amino acid sequence. Additional sequences, such as pro- or spacer-sequences which may or may not carry specific processing signals can also be included in the constructions to facilitate accurate processing of precursor molecules. Alternatively, fused proteins can be generated containing internal processing signals which allow proper maturation in vivo or in vitro. For example, the processing signals contain Lys-Arg, which is recognized by a yeast endopeptidase located in the Golgi membranes.

A DNA sequence containing yeast transcription termination signals is preferably the 3' flanking sequence of a yeast gene which contains proper signals for transcription termination and polyadenylation. Suitable 3' flanking sequences are for example those of the yeast gene naturally linked to the promoter used. The preferred flanking sequence is that of the yeast PH05 gene.

If a hybrid protein comprising a membrane-bound glycosyltransferase is expressed in yeast, the preferred yeast hybrid vector comprises an expression cassette comprising a yeast promoter, a DNA sequence encoding said hybrid protein, which DNA sequence is controlled by said promoter, and a DNA sequence containing yeast transcription termination signals. If the DNA encodes a hybrid protein comprising a membrane-bound glycosyltransferase there is no need for an additional signal sequence.

In case the hybrid protein to be expressed comprises two soluble glycosyltransferases, the preferred yeast hybrid vector comprises an expression cassette comprising a yeast promoter operably linked to a first DNA sequence encoding a signal peptide linked in the proper reading frame to a second DNA sequence encoding hybrid protein and a DNA sequence containing yeast transcription termination signals.

The hybrid vectors according to the invention are prepared by methods known in the art, for example by linking the expression cassette comprising a yeast promoter and a DNA sequence coding for a glycosyltransferase, or a variant thereof, which DNA sequence is

- 10 -

controlled by said promoter, or the several constituents of the expression cassette, and the DNA fragments containing selective genetic markers for yeast and for a bacterial host and origins of replication for yeast and for a bacterial host in the predetermined order, i.e. in a functional array.

The hybrid vectors of the invention are used for the transformation of the yeast strains described below.

The invention concerns furthermore a yeast strain which has been transformed with a hybrid vector of the invention.

Suitable yeast host organisms are strains of the genus Saccharomyces, especially strains of Saccharomyces cerevisiae. Said yeast strains include strains which, optionally, have been cured of endogenous two-micron plasmids and/or which optionally lack yeast peptidase activity(ies), e.g. peptidase *ysc* $\alpha$ , *ysc*A, *ysc*B, *ysc*Y and/or *ysc*S activity.

The yeast strains of the invention are used for the preparation of a hybrid protein of the invention.

The transformation of yeast with the hybrid vectors according to the invention is accomplished by methods known in the art, for example according to the methods described by Hinnen et al. (Proc. Natl. Acad. Sci. USA (1978) 75, 1929) and Ito et al. (J. Bact. (1983) 153, 163-168).

The transformed yeast strains are cultured using methods known in the art.

Thus, the transformed yeast strains according to the invention are cultured in a liquid medium containing assimilable sources of carbon, nitrogen and inorganic salts.

Various carbon sources are usable. Examples of preferred carbon sources are assimilable carbohydrates, such as glucose, maltose, mannitol, fructose or lactose, or an acetate such as sodium acetate, which can be used either alone or in suitable mixtures. Suitable nitrogen sources include, for example, amino acids, such as casamino acids, peptides and proteins and their degradation products, such as tryptone, peptone or meat extracts, furthermore yeast extract, malt extract, corn steep liquor, as well as ammonium salts, such as ammonium chloride, sulphate or nitrate which can be used either alone or in suitable

mixtures. Inorganic salts which may be used include, for example, sulphates, chlorides, phosphates and carbonates of sodium, potassium, magnesium and calcium. Additionally, the nutrient medium may also contain growth promoting substances. Substances which promote growth include, for example, trace elements, such as iron, zinc, manganese and the like, or individual amino acids.

Due to the incompatibility between the endogenous two-micron DNA and hybrid vectors carrying its replicon, yeast cells transformed with such hybrid vectors tend to lose the latter. Such yeast cells have to be grown under selective conditions, i.e. conditions which require the expression of a plasmid-encoded gene for growth. Most selective markers currently in use and present in the hybrid vectors according to the invention (infra) are genes coding for enzymes of amino acid or purine biosynthesis. This makes it necessary to use synthetic minimal media deficient in the corresponding amino acid or purine base. However, genes conferring resistance to an appropriate biocide may be used as well [e.g. a gene conferring resistance to the amino-glycoside G418]. Yeast cells transformed with vectors containing antibiotic resistance genes are grown in complex media containing the corresponding antibiotic whereby faster growth rates and higher cell densities are reached.

Hybrid vectors comprising the complete two-micron DNA (including a functional origin of replication) are stably maintained within strains of Saccharomyces cerevisiae which are devoid of endogenous two-micron plasmids (so-called *cir*<sup>o</sup> strains) so that the cultivation can be carried out under non-selective growth conditions, i.e. in a complex medium.

Yeast cells containing hybrid plasmids with a constitutive promoter express the DNA encoding a glycosyltransferase, or a variant thereof, controlled by said promoter without induction. However, if said DNA is under the control of a regulated promoter the composition of the growth medium has to be adapted in order to obtain maximum levels of mRNA transcripts, e.g. when using the PH05 promoter the growth medium must contain a low concentration of inorganic phosphate for derepression of this promoter.

The cultivation is carried out by employing conventional techniques. The culturing conditions, such as temperature, pH of the medium and fermentation time are selected in such a way that maximal levels of the heterologous protein are produced. A chosen yeast strain is e.g. grown under aerobic conditions in submerged culture with shaking or stirring at a temperature of about 25° to 35°C, preferably at about 28°C, at a pH value of from 4 to 7, for example at approximately pH 5, and for at least 1 to 3 days, preferably as long as

satisfactory yields of protein are obtained.

After expression in yeast the hybrid protein of the invention is either accumulated inside the cells or secreted by the cells. In the latter case the hybrid protein is found within the periplasmic space and/or in the culture medium. The enzymatic activity may be recovered e.g. by obtaining the protein from the cell or the culture supernatant by conventional means.

For example, the first step usually consists in separating the cells from the culture fluid by centrifugation. In case the hybrid protein has accumulated within the cells, the enzymatic activity is recovered by cell disruption. Yeast cells can be disrupted in various ways well-known in the art: e.g. by exerting mechanical forces such as shaking with glass beads, by ultrasonic vibration, osmotic shock and/or by enzymatic digestion of the cell wall. If desired, the crude extracts thus obtainable can be directly used for glycosylation. Further enrichment may be achieved for example by differential centrifugation of the cell extracts and/or treatment with a detergent, such as Triton.

In case the hybrid protein is secreted by the yeast cell into the periplasmic space, a simplified isolation protocol can be used: the protein is isolated without cell lysis by enzymatic removal of the cell wall or by chemical agents, e.g. thiol reagents or EDTA, which gives rise to cell wall damages permitting the produced hybrid protein to be released. In case the hybrid protein of the invention is secreted into the culture broth, the enzymatic activity can be isolated directly therefrom.

Methods suitable for the purification of the crude hybrid protein include standard chromatographic procedures such as affinity chromatography, for example with a suitable substrate, antibodies or Concanavalin A, ion exchange chromatography, gel filtration, partition chromatography, HPLC, electrophoresis, precipitation steps such as ammonium sulfate precipitation and other processes, especially those known from the literature.

In order to detect glycosyltransferase activity assays known from the literature can be used. For example, galactosyltransferase activity can be measured by determining the amount of radioactively labelled galactose incorporated into a suitable acceptor molecule such as a glycoprotein or a free sugar residue. Analogously, sialyltransferase activity may be assayed e.g. by the incorporation of sialic acid into a suitable substrate. For a hybrid protein exhibiting two different glycosyltransferase activities the activities may be

- 13 -

assessed individually or together in a 'single pot assay'.

A hybrid protein of the invention is useful e.g. for the synthesis or modification of glycoproteins, oligosaccharides and glycolipids. If the hybrid molecule comprises two different glycosyltransferase activities glycosylation in a one pot reaction is preferred.

The invention especially concerns the hybrid proteins, the recombinant DNA molecules coding therefor, the hybrid vectors and the transformed yeast strains, and the processes for the preparation thereof, as described in the Examples.

In the Examples, the following abbreviations are used: GT = galactosyltransferase (EC 2.4.1.22), PCR = polymerase chain reaction; ST = sialyltransferase (EC 2.4.99.1).

Example 1: Cloning of the galactosyltransferase (GT) cDNA from HeLa cells

GT cDNA is isolated from HeLa cells (Watzele, G. and Berger, E.G. (1990)

Nucleic Acids Res. 18, 7174) by the polymerase chain reaction (PCR) method:

1.1 Preparation of poly(A)<sup>+</sup>RNA from HeLa cells

For RNA preparation HeLa cells are grown in monolayer culture on 5 plates (23x23 cm).

The rapid and efficient isolation of RNA from cultured cells is performed by extraction with guanidine-HCl as described by Mac Donald, R.J. et al (Meth. Enzymol. (1987) 152, 226-227). Generally, yields are about 0.6 - 1 mg total RNA per plate of confluent cells.

Enrichment of poly(A)<sup>+</sup>RNA is achieved by affinity chromatography on oligo(dT)-cellulose according to the method described in the Maniatis manual (Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual (2nd edition), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA), applying 4 mg of total RNA on a 400 µl column. 3 % of the loaded RNA are recovered as enriched poly(A)<sup>+</sup>RNA which is stored in aliquots precipitated with 3 volumes of ethanol at -70°C until it is used.

1.2 First strand cDNA synthesis for PCR

Poly(A)<sup>+</sup>RNA (mRNA) is reverse-transcribed into DNA by Moloney Murine Leukemia Virus RNase H<sup>-</sup> Reverse Transcriptase (M-MLV H<sup>-</sup> RT) (BRL). In setting up the 20 µl reaction mix, the protocol provided by BRL is followed with minor variations: 1 µg of HeLa cell poly(A)<sup>+</sup>RNA and 500 ng Oligo(dT)<sub>12-18</sub> (Pharmacia) in 11.5 µl sterile H<sub>2</sub>O are

heated to 70°C for 10 min and then quickly chilled on ice. Then 4 µl reaction buffer provided by BRL (250 mM Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl<sub>2</sub>), 2 µl 0.1 M dithiothreitol, 1 µl mixed dNTP (10 mM each dATP, dCTP, dGTP, dTTP, Pharmacia), 0.5 µl (17.5 U) RNAGuard (RNase Inhibitor of Pharmacia) and 1 µl (200 U)M-MLVH- RT are added. The reaction is carried out at 42°C and stopped after 1 h by heating the tube to 95°C for 10 min.

In order to check the efficiency of the reaction an aliquot of the mixture (5 µl) is incubated in the presence of 2 µCi α-<sup>32</sup>P dCTP. By measuring the incorporated dCTP, the amount of cDNA synthesized is calculated. The yield of first strand synthesis is routinely between 5 and 15 %.

### 1.3 Polymerase chain reaction

The oligodeoxynucleotide primers used for PCR are synthesized *in vitro* by the phosphoramidite method (M.H. Caruthers, in Chemical and Enzymatic Synthesis of Gene Fragments, H.G. Gassen and A. Lang, eds., Verlag Chemie, Weinheim, FRG) on an Applied Biosystems Model 380B synthesizer. They are listed in Table 1.

Table 1: PCR-primers

primer	sequence (5' to 3') <sup>1)</sup>	corresponding to bp in GT cDNA <sup>2)</sup>
P1up (KpnI)	<b>cgcgg<u>t</u>ACCCTTCTTAAAGCGGCGGCGGGAAAGATG</b>	( -26) - 3
P1 (EcoRI)	<b>g<u>cc</u>gaat<u>c</u>ATGAGGCTCGGGAGCCGCTCCTGAGCG</b>	1 - 28
P3 (SacI)	<b>CTGG<u>AG</u>CTCGGCAAAGCAGAACCC</b>	448 - 473
P2d (EcoRI)	<b>g<u>cc</u>gaa<u>T</u>TCAGTCTTACCTGTACCAAAAGTCCTA</b>	1222-1192
P4 (HindIII)	<b>cc<u>ca</u>ag<u>ct</u>TGGAATGATGATGGCCACCTTGTGAGG</b>	546- 520

1) Capital letters represent sequences from GT, small letters are additional sequences, sites for restriction enzymes are underlined. Codons for 'start' and 'stop' of RNA translation are highlighted in boldface.

2) GT cDNA sequence from human placenta published in GenBank (Accession No. M22921)..

Standard PCR-conditions for a 30 µl incubation mixture are: 1 µl of the Reverse Transcriptase reaction (see Example 1.2), containing about 5 ng first strand cDNA, 15 pmol each of the relevant primers, 200 µmol each of the four deoxynucleoside triphosphates

- 15 -

(dATP, dCTP, dGTP and dTTP) in PCR-buffer (10 mM Tris-HCl pH 8.3 (at 23°C), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.001 % gelatine) and 0.5 U AmpliTaq Polymerase (Perkin Elmer). The amplification is performed in the Thermocycler 60 (Biomed) using the following conditions: 0.5 min denaturing at 95°C, 1 min annealing at 56°C, and 1 min 15 sec extension at 72°C, for a total of 20 - 25 cycles. In the last cycle, primer extension at 72°C is carried out for 5 min.

For sequencing and subcloning, the HeLa GT cDNA is amplified in two overlapping pieces, using different primer combinations:

- (1) Fragment P1 - P4: Primers P1 and P4 are used to amplify a DNA fragment covering nucleotide positions 7-555 in the nucleotide sequence depicted in SEQ ID NO. 1.
- (2) Fragment P3 - P2d: Primers P3 and P2d are used to amplify a DNA fragment covering nucleotide positions 457 - 1229 in the nucleotide sequence depicted in SEQ ID NO. 1.

In order to avoid errors during amplification four independent PCRs are carried out for each fragment. Also primer P1up (KpnI) in combination with primer P4 is used to determine the DNA sequence followed by the 'start' codon.

After PCR amplification, fragment P1 - P4 is digested with the restriction enzymes EcoRI and HindIII, analysed on a 1.2 % agarose gel, eluted from the gel by GENECLEAN (BIO 101) and subcloned into the vector pUC18 (Pharmacia), digested with the same enzymes. Fragment P3 - P2d is digested with SacI and EcoRI, analysed on a 1.2 % gel, eluted and subcloned into pUC18, digested with SacI and EcoRI. The resulting subclones are pUC18/P1 - P4 and pUC18/P3 - P2d, respectively. For subcloning, ligation and transformation of *E. coli* strain DH5 $\alpha$ , standard protocols are followed as described in Example 2. Minipreparations of Plasmids pUC18/P1 - P4 and pUC18/P3 - P2d are used for dideoxy-sequencing of denatured double-stranded DNA with the T7 polymerase Sequencing kit (Pharmacia). M13/pUC sequencing primers and reverse sequencing primers (Pharmacia) are applied to sequence overlapping fragments produced from both DNA strands by digestion with various restriction enzymes. Further subcloning of restriction fragments of the GT gene is necessary for extensive sequencing of overlapping fragments of both strands. The sequence of fragments amplified by independent PCRs shows that the error of amplification is less than 1 in 3000 nucleotides. The complete nucleotide sequence of the HeLa cell GT cDNA which is presented in SEQ ID NO. 1 is

99.2 % homologous to that of human placenta (Genbank Accession No. M22921). Three differences are found:

(a) Three extra base pairs at nucleotide positions 37-39 (SEQ ID NO. 1) resulting in one extra amino acid (Ser) in the N-terminal region of the protein; (b) bp 98 to 101 are 'CTCT' instead of 'TCTG' in the sequence of human placenta, leading to two conservative amino acid substitutions (Ala Leu instead of ValTyr) at amino acid positions 31 and 32 in the membrane spanning domain of GT; (c) the nucleotide at position 1047 is changed from 'A' to 'G' without ensuing a change in amino acid sequence.

The two overlapping DNA-fragments P1 - P4 and P3 - P2d encoding the HeLa GT cDNA are joined via the NotI restriction site at nucleotide position 498 which is present in both fragments.

The complete HeLa cell GT cDNA is cloned as a 1.2 kb EcoRI-EcoRI restriction fragment in plasmid pIC-7, a derivative of pUC8 with additional restriction sites in the multicloning site (Marsh, J.L., Erfle, M. and Wykes, E.J. (1984) Gene 32, 481-485), resulting in vector p4AD113. SEQ ID NO. 1 shows the DNA sequence of the EcoRI-HindIII fragment from plasmid p4AD113 comprising HeLa cell cDNA coding for full-length GT (EC 2.4.1.22), said fragment having the following features:

from 6 to 1200 bp	cDNA sequence coding for HeLa cell galactosyltransferase
from 1 to 6 bp	EcoRI site
from 497 to 504 bp	NotI site
from 1227 to 1232 bp	EcoRI site
from 1236 to 1241 bp	EcoRV site
from 1243 to 1248 bp	BglII site

For the purpose of creating the GT expression cassette the EcoRI restriction site (bp 1227) at the 3' end of the cDNA sequence is deleted as follows: vector p4AD113 is first linearized by digestion with EcoRV and then treated with alkaline phosphatase. Furthermore, 1 µg of the linearised plasmid DNA is partially digested with 0.25 U EcoRI for 1 h at 37°C. After agarose gel electrophoresis a fragment corresponding to the size of the linearized plasmid (3.95 kb) is isolated from the gel by GENECLEAN (Bio 101). The protruding EcoRI end is filled in with Klenow polymerase as described in the Maniatis manual (supra). After phenolisation and ethanol precipitation the plasmid is religated and used to transform E. coli DH5 $\alpha$  (Gibco/BRL). Minipreparation of plasmids are prepared

from six transformants. The plasmids obtained are checked by restriction analysis for the absence of the EcoRI and EcoRV restriction sites at the 3' end of HeLa GT cDNA. The plasmid designated p4AE113 is chosen for the following experiments, its DNA sequence being identical to that of plasmid p4AD113, with the exception that bp 1232-1238 with the EcoRI-EcoRV restriction sites are deleted.

Example 2: Construction of expression cassettes for full length GT

For heterologous expression in Saccharomyces cerevisiae the full length HeLa GT cDNA sequence (SEQ ID NO. 1) is fused to transcriptional control signals of yeast for efficient initiation and termination of transcription. The promoter and terminator sequences originate from the yeast acid phosphatase gene (PH05) (EP 100561). A short, 173 bp PH05 promoter fragment is used, which is devoid of all regulatory elements and therefore behaves as a constitutive promoter.

The GT cDNA sequence is combined with a yeast 5' truncated PH05 promoter fragment and transcription terminator sequences as follows:

(a) Full length HeLa GT cDNA sequence:

Vector p4AE113 with the full length GT cDNA sequence is digested with the restriction enzymes EcoRI and BglII. The DNA fragments are electrophoretically separated on a 1 % agarose gel. A 1.2 kb DNA fragment containing the complete cDNA sequence for HeLa GT is isolated from the gel by adsorption to glasmilk, using the GENECLEAN kit (BIO 101). On this fragment the 'ATG' start codon for protein synthesis of GT is located directly behind the restriction site for EcoRI, whereas the stop codon 'TAG' is followed by 32 bp contributed by the 3'untranslated region of HeLa GT and the multiple cloning site of the vector with the BglII restriction site.

(b) Vector for amplification in E. coli:

The vector for amplification, plasmid p31R (cf. EP 100561), a derivative of pBR322, is digested with the restriction enzymes BamHI and SalI. The restriction fragments are separated on a 1 % agarose gel and a 3.5 kb vector fragment is isolated from the gel as described before. This DNA fragment contains the large SalI - HindIII vector fragment of the pBR322 derivative as well as a 337 bp PH05 transcription terminator sequence in place of the HindIII - BamHI sequence of pBR322.

(c) Construction of plasmid p31/PH05(-173)RIT

The 5' truncated PHO5 promoter fragment without phosphate regulatory elements is isolated from plasmid p31/PHO5(-173)RIT.

Plasmid p31 RIT12 (EP 288435) comprises the full length, regulated PHO5 promoter (with an EcoRI site introduced at nucleotide position -8 on a 534bp BamHI - EcoRI fragment, followed by the coding sequence for the yeast invertase signal sequence (72bp EcoRI - XhoI) and the PHO5 transcription termination signal (135bp XhoI - HindIII) cloned in a tandem array between BamHI and HindIII of the pBR322 derived vector.

The constitutive PHO5(-173) promoter element from plasmid pJDB207/PHO5(-173)-YHIR (EP 340170) comprises the nucleotide sequence of the yeast PHO5 promoter from nucleotide position -9 to -173 (BstEII restriction site), but has no upstream regulatory sequences (UASp). The PHO5(-173) promoter, therefore, behaves like a constitutive promoter. The regulated PHO5 promoter in plasmid p31RIT12 is replaced by the short, constitutive PHO5 (-173) promoter element in order to obtain plasmid p31/PHO5 (-173) RIT.

Plasmids p31RIT12 (EP 288435) and pJDB207/PHO5(-173)-YHIR (EP 340170) are digested with restriction endonucleases SalI and EcoRI. The respective 3.6 kb and 0.4 kb SalI - EcoRI fragments are isolated on a 0.8 % agarose gel, eluted from the gel, ethanol precipitated and resuspended in H<sub>2</sub>O at a concentration of 0.1 pmoles/μl. Both DNA fragments are ligated and 1 μl aliquots of the ligation mix are used to transform E. coli HB101 (ATCC) competent cells. Ampicillin resistant colonies are grown individually in LB medium supplemented with ampicillin (100 μg/ml). Plasmid DNA is isolated according to the method of Holmes, D.S. et al. (Anal. Biochem. (1981) 144, 193) and analysed by restriction digests with SalI and EcoRI. The plasmid of one clone with the correct restriction fragments is referred to as p31/PHO5(-173)RIT.

(d) Construction of plasmid pGTB1135

Plasmid p31/PHO5(-173)RIT is digested with the restriction enzymes EcoRI and SalI. After separation on a 1 % agarose gel, a 0.45 kb SalI - EcoRI fragment (fragment (c)) is isolated from the gel by GENECLEAN (BIO 101). This fragment contains the 276 bp SalI-BamHI sequence of pBR322 and the 173bp BamHI(BstEII)-EcoRI constitutive PHO5 promoter fragment. The 0.45 kb SalI-EcoRI fragment is ligated to the 1.2 kb EcoRI - BglIII GT cDNA (fragment (a)) and the 3.5 kb BamHI-SalI vector part for amplification in E. coli with the PHO5 terminator (fragment (b)) described above.

The three DNA fragments (a) to (c) are ligated in a 12 µl ligation mixture: 100 ng of DNA fragment (a) and 30 ng each of fragments (b) and (c) are ligated using 0.3 U T4 DNA ligase (Boehringer) in the supplied ligase buffer (66 mM Tris-HCl pH 7.5, 1 mM dithioerythritol, 5 mM MgCl<sub>2</sub>, 1 mM ATP) at 15°C for 18 hours. Half of the ligation mix is used to transform competent cells of *E. coli* strain DH5α (Gibco/BRL). For preparing competent cells and for transformation, the standard protocol as given in the Maniatis manual (supra) is followed. The cells are plated on selective LB-medium, supplemented with 75 µg/ml ampicillin and incubated at 37°C. 58 transformants are obtained. Minipreparations of plasmid are performed from six independent transformants by using the modified alkaline lysis protocol of Birnboim, H.C. and Doly, J. as described in the Maniatis manual (supra). The isolated plasmids are characterized by restriction analysis with four different enzymes (EcoRI, PstI, HindIII, SalI, also in combination). All six plasmids show the expected fragments. One correct clone is referred to as pGTB 1135. Plasmid pGTB 1135 contains the expression cassette with the full-length HeLaGT cDNA under the control of the constitutive PH05 (-173) promoter fragment, and the PH05 transcriptional terminator sequence. This expression cassette can be excised from vector pGTB 1135 as a 2 kb SalI - HindIII fragment.

#### Example 3: Construction of plasmids pA1 and pA2

##### 3.1 PCR for site-directed mutagenesis

In order to knock out the stop codon of the GT coding sequence and to allow for an in frame fusion with ST a frame shift mutation and a point mutation are introduced into the cDNA coding for HeLa GT. The oligonucleotide primers used for PCR are synthesized in vitro according to the phosphoramidite method (supra) and listed in Table 2.

Table 2: PCR-primers

primer	sequence (5' to 3') <sup>1)</sup>	corresponding to bp in SEQ ID NO.3
P3 (SacI)	CTGG <u>AGCTCGTGGCAAAGCAGAACCC</u>	457 - 482
P2A1 (BamHI)	gggg <u>aTCCTAGCTCG-TGTCCC</u>	1205 - 1189
P2B1 (BamHI)	gggg <u>aTCCCAGCTCG-TGTCCC</u>	1205 - 1189

<sup>1)</sup> Capital letters represent sequences from GT, small letters are additional sequences, sites for restriction enzymes are underlined. Codons for 'start' and 'stop' of RNA translation are highlighted in boldface.

- 20 -

Standard PCR-conditions for a 30  $\mu$ l incubation mixture are: 1  $\mu$ l of the Reverse Transcriptase reaction mix containing about 5 ng first strand cDNA (see Example 1.2), 15 pmol each of the relevant primers, 200  $\mu$ mol each of the four deoxynucleoside triphosphates (dATP, dCTP, dGTP and dTTP) in PCR-buffer (10 mM Tris-HCl pH 8.3 (at 23°C), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.001 % gelatine) and 0.5 U AmpliTaq Polymerase (Perkin Elmer). The amplification is performed in the Thermocycler 60 (Biomed) using the following conditions: 0.5 min denaturing at 95°C, 1 min annealing at 56°C, and 1 min 15 sec extension at 72°C, for a total of 20 - 25 cycles. In the last cycle, primer extension at 72°C is carried out for 5 min.

For sequencing and subcloning, the HeLa GT cDNA is amplified as described above, yielding "mutated" fragments:

- (3) Fragment P3-P2A1: primers P3 and P2A1 are used to amplify a 0.77 kb fragment covering nucleotides 457-1205 in the sequence depicted in SEQ ID NO. 3
- (4) Fragment P3-P2B1: primers P3 and P2B1 are used to amplify a 0.77 kb fragment covering nucleotide positions 457-1205 in the sequence depicted in SEQ ID NO. 3.

### 3.2 Construction of plasmids pA1 and pA2

Fragments P3-P2A1 and P3-P2B1, respectively, are amplified by PCR, digested with BamH1 and SacI and subcloned into vector pUC18 (Pharmacia), digested with the same enzyme to produce plasmids pA1 and pA2.

#### Example 4: Cloning of the sialyltransferase (ST) cDNA from human HepG2 cells

ST cDNA is isolated from HepG2 cells by PCR in analogy to GT cDNA. Preparation of poly (A)<sup>+</sup>RNA and first strand cDNA synthesis are performed as described in Example 1. The primers (Microsynth) listed in Table 3 are used for PCR.

Table 3: PCR-primers

primer	sequence (5' to 3') <sup>1)</sup>	corresponding to bp in ST cDNA <sup>2)</sup>
	<b>PstI/EcoRI</b>	
SIA1	<u>cgctgcagaattcaaa</u> <b>ATGATT</b> CACACCAACCTGAAGAAAAAGT	1 - 28
	<b>BamHI</b>	
SIA3	<u>cgcggat</u> <b>CCTGTGCTTAGCAGTGAATGGTCCGGAAAGCC</b>	1218 - 1198

<sup>1)</sup> Capital letters represent sequences from ST, small letters are additional sequences with sites for restriction enzymes (underlined). Codons for 'start' and 'stop' for protein synthesis are indicated in boldface.

<sup>2)</sup> ST cDNA sequence from human placenta as published in EMBL Data Bank (Accession No. X17247)

HepG2 ST cDNA can be amplified as one DNA fragment of 1.2 kb using the primers SIA1 and SIA3. PCR is performed as described for GT cDNA under slightly modified cycling conditions: 0.5 min denaturing at 95°C, 1 min. 15 sec annealing at 56°C, and 1 min 30 sec extension at 72°C, for a total of 25-35 cycles. In the last cycle, primer extension at 72°C is carried out for 5 min.

After PCR amplification, the 1.2 kb fragment is digested with the restriction enzymes BamHI and PstI, analysed on a 1.2 % agarose gel, eluted from the gel and subcloned into the vector pUC18. The resulting subclone is designated pSIA2. The nucleotide sequence of the PstI-BamHI fragment from plasmid pSIA2 comprising HepG2 cDNA coding for full-length sialyltransferase is presented in SEQ ID NO. 3, said fragment having the following features:

from 15 to 1232 bp	cDNA sequence coding for HepG2 cell sialyltransferase
from 1 to 6 bp	PstI site
from 6 to 11 bp	EcoRI site
from 144 to 149 bp	EcoRI site
from 1241 to 1246 bp	BamHI site.

#### Example 5: Construction of plasmids pA1ST and pB1ST

a) Plasmid pSIA2 is double digested using EcoR1/BamH1 and the ensuing 1098 bp fragment (fragment (a)) is isolated. The fragment codes for a soluble ST designated ST<sub>(44-406)</sub> starting at amino acid position 44 (Glu) and extending to amino acid position

- 22 -

406 (Cys) (SEQ ID NO. 4).

b) Plasmids A1 and B1 are linearized by BamH1 digestion, treated with alkaline phosphatase and separated from contaminating enzymes by gel electrophoresis using GENECLEAN (Bio 101).

c) Fragment (a) is linked to fragment (b) by means of an adaptor sequence from equimolar amounts of the synthesized oligonucleotides (Microsynth):

5' GATCCGTCGACCTGCAG 3' and 5' AATTCA~~G~~GCAGGTCGACG 3' for the complementary strand. The oligonucleotides are annealed to each other by first heating to 95°C and then slowly cooling to 20°C. Ligation is carried out in 12 µl of ligase buffer (66 mM Tris-HCl pH 7.5, 1 mM dithioerythritol, 5 mM MgCl<sub>2</sub>, 1 mM ATP) at 16°C for 18 hours. The sequences at the junction of GT and ST are as follows:

pA1ST: BamH1 Adaptor (bold) EcoRI

GGG ACA CGA GCT **AGG ATC CGT CGA CCT GCA GAA TTC** CAG GTG  
Gly Thr Arg Ala Arg Ile Arg Arg Pro Ala Glu Phe Gln Val

pB1ST:

GGG ACA CGA GCT **GGG ATC CGT CGA CCT GCA GAA TTC** CAG GTG  
Gly Thr Arg Ala Gly Ile Arg Arg Pro Ala Glu Phe Gln Val

The ligated plasmids pA1ST and pB1ST are transformed into E. coli strain DH5 $\alpha$ . Plasmid DNA of 6 transformants from each transformation is isolated and digested with EcoRI to test the orientation of the BamHI insert. Plasmids with a 3900 bp together with a 700 bp EcoRI fragment are used for the next step.

#### Example 6: Construction of the GT-ST expression vectors YEPGSTa and YEPGSTb

##### 6.1 Isolation of a NotI-BamHI fragment coding for the GT C-terminus fused to ST

Plasmids pA1ST and pB1ST are linearised by cutting with NotI and then partially digested with BamHI. After gel electrophoresis a 1900 bp NotI-BamHI fragment coding for the GT C-terminus fused to ST is isolated.

##### 6.2 Construction of the YEPGTB vector

The episomal yeast vector YEP352 (S.E. Hill et al., Yeast 2, 163-167, 1986) is used to construct the YEPGTB vector which contains the constitutive PHO5 promoter, the cDNA coding for full length GT and the PHO5 transcriptional terminator sequence.

YEP352 is digested with the restriction enzymes SalI and HindIII at the multiple cloning site. After separation over an 0.8% agarose gel the linearized vector is isolated as a 5.2 kb DNA fragment (vector part) from the gel with the GENECLEAN kit (Bio 101). Vector

pGTB1135 (Example 2) is also digested with the restriction enzymes SalI and HindIII. A 2.0 kb fragment containing the expression cassette with the constitutive promoter is isolated. Ligation of the yeast vector and the expression cassette is carried out as follows: in a 12  $\mu$ l ligation mix, 80 ng of the vector part (5.2 kb fragment) is combined with 40 ng of the 2.0 kb SalI-HindIII fragment using 0.3U ligase (Boehringer) in the supplied buffer (66 mM Tris-HCl pH 7.5, 1 mM dithioerythritol, 5 mM MgCl<sub>2</sub>, 1 mM ATP) for 18 hours at 15°C. The ligation mix is used to transform E.coli DH5 $\alpha$  as described above. 24 transformants are obtained. Four independent colonies are chosen for minipreparation of plasmids. The isolated plasmids are characterized by restriction analysis: all four analyzed plasmids (YEPGTB 21-24) show the expected restriction patterns. YEPGTB24 is used for further experiments.

#### 6.3 Isolation of the fragment coding for the N-terminal part of GT.

YEPGTB24 carrying the whole constitutive expression cassette for GT in the yeast-E.coli shuttle vector YEP352 is cut with NotI and HindIII and a 6.3 kb fragment is isolated after gel electrophoresis.

#### 6.4 PHO5-terminator sequence

Plasmid p31 RIT12 (EP 288435) is cut with BamHI and Hind III and a 400 bp fragment carrying the PHO5 terminator sequence is isolated.

Fragments isolated as described in 6.1 (1.9 kb NotI-BamHI fragment, 6.3 (6.3 kb HindIII-NotI fragment) and 6.4 (0.4 kb BamHI-HindIII fragment) are ligated to yield plasmids YEPGSTa and YEPGSTb, respectively, which are transformed in the E.coli strain DH5 $\alpha$ . Plasmid DNA of transformants carrying the predicted pattern of BamHI fragments with 5580 bp, 1375 bp, 1150 bp and 276 bp are used for yeast transformation. The nucleotide sequences of the cDNAs coding for the hybrid glycosyltransferases designated GT-STa and GT-STb are presented in SEQ ID NOs. 5 and 7, respectively, said sequences having the following common features:

from 1 to 1188 bp	cDNA sequence coding for HeLa cell
	GT <sub>(1-396)</sub> (cf. SEQ ID NO.1)
from 1189 to 1212 bp	Adaptor
from 1213 to 2301 bp	cDNA sequence coding for HepG2 cell
	ST <sub>(44-406)</sub>

Example 7: Transformation of yeast strain BT 150

CsCl-purified DNA of the expression vectors YEPGSTa and YEPGSTb is prepared following the protocol of R. Treisman in the Maniatis manual (supra). The protease deficient *S. cerevisiae* strain BT 150 (MAT $\alpha$ , his4, leu2, ura3, pral, prb1, prc1, cps1) is transformed with about 1  $\mu$ g of plasmids YEPGSTa and YEPGSTb, respectively, according to the lithium-acetate transformation method (Ito et al., J. Bact. (1983) 153, 163-168). Approximately 200 transformants are obtained with YEPGSTa and YEPGSTb on SD plates (0.67% yeast nitrogen base without amino acids, 2% glucose, 2% agarose supplemented with leucine (30  $\mu$ g/ml) and histidine (20  $\mu$ g/ml). Single transformed yeast cells are selected and referred to as *Saccharomyces cerevisiae* BT 150/YEPGSTa and *Saccharomyces cerevisiae* BT 150/YEPGSTb, respectively.

Example 8: Enzyme activity of the GT-ST hybrid proteins**8.1 Preparation of cell extracts****Preparation of cell extracts**

Cells of transformed *Saccharomyces cerevisiae* strains BT 150 are each grown under uracil selection in yeast minimal media (Difco) supplemented with histidine and leucine. The growth rate of the cells is not affected by the introduction of any of the expression vectors. Exponentially growing cells (at OD<sub>578</sub> of 2.0) or stationary cells are collected by centrifugation, washed once with 50 mM Tris-HCl buffer pH 7.4 (buffer 1) and resuspended in buffer 1 at a concentration corresponding to 2 OD<sub>578</sub>. A 60 ml culture (120 OD<sub>578</sub>) of yeast cells is washed, pelleted and subjected to mechanical breakage by vigorous shaking on a vortex mixer with glass beads (0.45 - 0.5 mm diameter) for 4 min with intermittent cooling. The crude extracts are used directly for determination of enzyme activity.

**8.2 Protein assay**

The protein concentration is determined by use of the BCA-Protein Assay Kit (Pierce).

**8.3 Assay for GT activity**

GT activity can be measured with radiochemical methods using either ovalbumin, a glycoprotein which solely exposes GlcNAc as acceptor site, or free GlcNAc as acceptor substrates. Cell extracts (of 1 - 2 ODs<sub>578</sub> of cells) are assayed for 30 min at 37°C in a 100  $\mu$ l incubation mixture containing 35 mM Tris-HCl pH 7.4, 25 nCi UDP-<sup>14</sup>C-Gal (1.25 mCi/mmol), 1  $\mu$ mol MnCl<sub>2</sub>, 2 % Triton X-100 and 1 mg ovalbumin or 20 mM GlcNAc as acceptor substrates. The reaction is terminated by acid precipitation of the

- 25 -

protein and the amount of  $^{14}\text{C}$  galactose incorporated into ovalbumin is determined by liquid scintillation counting (Berger, E.G. et al. (1978) *Eur. J. Biochem.* 90, 213-222). For GlcNAc as acceptor substrate, the reaction is terminated by the addition of 0.4 ml ice cold  $\text{H}_2\text{O}$  and the unused UDP- $^{14}\text{C}$ -galactose is separated from  $^{14}\text{C}$  products on an anion exchange column (AG X1-8, BioRad) as described (Masibay, A.S. and Qasba, P.K. (1989) *Proc. Natl. Acad. Sci. USA* 86, 5733-5737). Assays are performed with and without acceptor molecules to assess the extent of hydrolysis of UDP-Gal by nucleotide pyrophosphatases. GT activity is determined in the crude extracts prepared from *Saccharomyces cerevisiae* BT 150/YPEGSTa and *Saccharomyces cerevisiae* BT 150/YPEGSTb.

#### 8.4 Determination of optimum detergent activation

The standard assay of GT activity according to Example 8.3 using 10 mM GlcNAc as acceptor substrate is carried out in presence of zero, 0.1, 0.5, 1.0, 2.0, 2.5 and 4 % Triton X-100 in the assay. 2 % Triton X-100 induce a two fold stimulation as compared with zero % Triton.

#### 8.5 Assay for lactose synthase activity

The assay is carried out and terminated as indicated in Example 8.3 for GlcNAc as acceptor with the following modifications: instead of GlcNAc, 30 mM glucose is used as acceptor. Other ingredients include: 1 mg/ml human  $\alpha$ -lactalbumin, 10 mM ATP. Optimum concentration of  $\alpha$ -lactalbumin is determined in a range of 0 to 4 mg/ml  $\alpha$ -lactalbumin. Maximum lactose synthase activity is observed at 1 mg/ml.

#### 8.6 Assay for ST activity

ST activity can be determined by measuring the amount of radiolabeled sialic acid which is transferred from CMP-sialic acid to a glycoprotein acceptor. In case of the use of a glycoprotein as acceptor such as asialofetuin, the reaction is terminated by acid precipitation using 5% (w/v) phosphotungstic acid and 5% (w/v) trichloroacetic acid. The precipitate is filtered using glass fiber filters (Whatman GFA), washed extensively with ice-cold ethanol and assessed for radioactivity by liquid scintillation counting (Hesford et al. (1984), *Glycoconjugate J.* 1, 141-153). In case of the use of oligosaccharides as acceptors such as lactose or LacNAc (N-acetyllactosamin), the reaction is terminated by addition of 0.4 ml ice-cold  $\text{H}_2\text{O}$ . The unused CMP- $^{14}\text{C}$ -sialic acid is retained on a 1 ml-column of AG1-X8, phosphate form, 100-200 mesh. The column is washed with 4.5 ml  $\text{H}_2\text{O}$  and eluted with 24 ml 5 mM  $\text{K}_2\text{HPO}_4$  buffer at pH 6.8. Eluant and wash

solution are pooled and assessed for radioactivity by liquid scintillation counting. Standard conditions are as follows: 20  $\mu$ l of yeast extracts (200 to 500  $\mu$ g protein) are incubated with 300  $\mu$ g asialofetuin in 2 mM imidazole buffer pH 7.4 and 3 nmoles CMP- $^{14}$ sialic acid (specific activity: 2.7 mCi/mmol), Triton X-100 0.5 %. ST-activity is found in the crude extracts prepared from *Saccharomyces cerevisiae* BT 150/YEPGSTa and *Saccharomyces cerevisiae* BT 150/YEPGSTb.

### 8.7 Combined GT and ST activity

Yeast extracts prepared from *Saccharomyces cerevisiae* BT 150/YEPGSTa and *Saccharomyces cerevisiae* BT 150/YEPGSTb are used to transfer Gal from UDPGal and sialic acid from CMPNeuAc to asialo-agalacto- $\alpha_1$  acid glycoprotein or GlcNAc according to the following conditions: 30  $\mu$ l of extract, 20  $\mu$ l of asialo-agalacto- $\alpha_1$  acid glycoprotein (prepared according to Hughes, R.C. and Jeanloz, R.W., (1966), *Biochemistry* 5, 253-258), 2 mM of unlabeled UDPGal, 60  $\mu$ M of CMP $^{14}$ -sialic acid (specific activity: 5.4 mCi/mmol) in 2 mM imidazole buffer, pH 7.4. ST-activity is shown by incorporation of  $^{14}$ C-sialic acid. Control incubation carried out in the absence of unlabeled UDPGal results in a 4 times less incorporation of  $^{14}$ C-sialic acid.

Similar incubations are carried out using 20 mM GlcNAc or 30 mM glucose (in presence of 0.1 mg/ml  $\alpha$ -lactalbumin) as acceptor and isolating the product according to 8.6. Linear incorporations of  $^{14}$ C-sialic acid are observed during 180 min. The assay system contains in a final volume of 1 ml: 3 mmol glucose, 1 mg  $\alpha$ -lactalbumin, 1 mM ATP, 1 mmol MnCl<sub>2</sub>, 20 mmol Tris-HCl, pH 7.4 20 nmol UDPGal, 12 nmol CMP $^{14}$ C-sialic acid (4.4 mCi/mmol specific activity) and 350  $\mu$ g protein (yeast extract). The reaction is terminated by adding 0.4 ml of ice-cold H<sub>2</sub>O. The mixture is passed over a 2 cm Bio-Rad Poly-Prep<sup>R</sup> column containing AG1-X8 A6, 100-200 mesh, phosphate form. The column is washed with 4.5 ml H<sub>2</sub>O and eluted with 24 ml 5 mM K<sub>2</sub>HPO<sub>4</sub> buffer at pH 6.8. 1 ml of the eluant is used for radioactivity measurement by liquid scintillation counting in 10 ml Instagel<sup>R</sup>.

### 8.8 Product identification of oligosaccharides synthesized by the GT-ST hybrid proteins

#### 8.8.1 Synthesis of 2,6 sialyllacNAc

The incubation mixture contains in a volume of 1.57 ml: 20 mmol GlcNAc, 10 mM ATP, 1 mM MnCl<sub>2</sub>, 5 mg Triton X-100, 200 mM UDPGal, 30 nmol CMP  $^{14}$ C-sialic acid (4.4 mCi/mmol specific activity) and 1000  $\mu$ g protein (yeast extract prepared from *Saccharomyces cerevisiae* BT 150/YEPGSTa and *Saccharomyces cerevisiae* BT 150/YEPGSTb, respectively). Incubation is carried out for 16 h at 37°C. The reaction is

terminated by adding 0.5 ml of H<sub>2</sub>O. The incubation mixture is separated on AG1-X8 as described in Example 8.7. The total eluant of the anion exchange column is lyophilized. Then, the residue is dissolved in 0.6 ml H<sub>2</sub>O followed by separation on a Biogel P2 column (200-400 mesh, 2x90 cm). The column is eluted with H<sub>2</sub>O at a temperature of 42.5°C at 5 ml/h. 0.5 ml fractions are collected and assessed for radioactivity in 100 µl aliquots (to which 4 ml Instagel<sup>R</sup> is added for liquid scintillation counting). The peak fractions containing <sup>14</sup>C are pooled, lyophilized and repurified on AG1-X8 as described in Example 8.7. The total eluant of 24 ml is lyophilized, the resulting residue dissolved in 300 µl H<sub>2</sub>O. This solution is subjected to preparative thin layer chromatography (Merck Alu plates coated with silicagel 60 F<sub>254</sub>) in a solvent system containing H<sub>2</sub>O/acetone/n-butanol 2/1.5/1.5 for 5 h and run against authentic standards including 50 mM sialyl 2,6-lactose and 2,6 sialyl LacNAc. After drying the products and standards are visualized using a spray containing 0.5 g thymol in 5 ml H<sub>2</sub>SO<sub>4</sub> (96 %) and 95 ml ethanol (96 %) followed by heating for 10 min at 130°C. The spots detected are found to be at identical positions as the corresponding authentic standards.

- 28 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: CIBA-GEIGY AG
- (B) STREET: Klybeckstr. 141
- (C) CITY: Basel
- (E) COUNTRY: SCHWEIZ
- (F) POSTAL CODE (ZIP): 4002
- (G) TELEPHONE: +41 61 69 11 11
- (H) TELEFAX: + 41 61 696 79 76
- (I) TELEX: 962 991

(ii) TITLE OF INVENTION: Proteins having glycosyltransferase activity

(iii) NUMBER OF SEQUENCES: 8

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1265 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- 29 -

(vi) ORIGINAL SOURCE:

(B) STRAIN: E. coli DH5alpha

(vii) IMMEDIATE SOURCE:

(B) CLONE: p4AD113

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 7..1200

(D) OTHER INFORMATION: /product= "full-length  
galactosyltransferase"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GAATTC ATG AGG CTT CGG GAG CCG CTC CTG AGC GGC AGC GCC GCG ATG 48  
Met Arg Leu Arg Glu Pro Leu Leu Ser Gly Ser Ala Ala Met  
1 5 10

CCA GGC GCG TCC CTA CAG CGG GCC TGC CGC CTG CTC GTG GCC GTC TGC 96  
Pro Gly Ala Ser Leu Gln Arg Ala Cys Arg Leu Leu Val Ala Val Cys  
15 20 25 30

GCT CTG CAC CTT GGC GTC ACC CTC GTT TAC TAC CTG GCT GGC CGC GAC 144  
Ala Leu His Leu Gly Val Thr Leu Val Tyr Tyr Leu Ala Gly Arg Asp  
35 40 45

CTG AGC CGC CTG CCC CAA CTG GTC GGA GTC TCC ACA CCG CTG CAG GGC 192  
Leu Ser Arg Leu Pro Gln Leu Val Gly Val Ser Thr Pro Leu Gln Gly  
50 55 60

GGC TCG AAC AGT GCC GCC ATC GGG CAG TCC TCC GGG GAG CTC CGG 240  
Gly Ser Asn Ser Ala Ala Ile Gly Gln Ser Ser Gly Glu Leu Arg  
65 70 75

- 30 -

ACC GGA GGG GCC CGG CCG CCT CCT CTA GGC GCC TCC TCC CAG CCG	288		
Thr Gly Gly Ala Arg Pro Pro Pro Pro Leu Gly Ala Ser Ser Gln Pro			
80	85	90	
CGC CCG GGT GGC GAC TCC AGC CCA GTC GTG GAT TCT GGC CCT GGC CCC	336		
Arg Pro Gly Gly Asp Ser Ser Pro Val Val Asp Ser Gly Pro Gly Pro			
95	100	105	110
GCT AGC AAC TTG ACC TCG GTC CCA GTG CCC CAC ACC ACC GCA CTG TCG	384		
Ala Ser Asn Leu Thr Ser Val Pro Val Pro His Thr Thr Ala Leu Ser			
115	120	125	
CTG CCC GCC TGC CCT GAG GAG TCC CCG CTG CTT GTG GGC CCC ATG CTG	432		
Leu Pro Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro Met Leu			
130	135	140	
ATT GAG TTT AAC ATG CCT GTG GAC CTG GAG CTC GTG GCA AAG CAG AAC	480		
Ile Glu Phe Asn Met Pro Val Asp Leu Glu Leu Val Ala Lys Gln Asn			
145	150	155	
CCA AAT GTG AAG ATG GGC GGC CGC TAT GCC CCC AGG GAC TGC GTC TCT	528		
Pro Asn Val Lys Met Gly Gly Arg Tyr Ala Pro Arg Asp Cys Val Ser			
160	165	170	
CCT CAC AAG GTG GCC ATC ATC ATT CCA TTC CGC AAC CGG CAG GAG CAC	576		
Pro His Lys Val Ala Ile Ile Ile Pro Phe Arg Asn Arg Gln Glu His			
175	180	185	190
CTC AAG TAC TGG CTA TAT TAT TTG CAC CCA GTC CTG CAG CGC CAG CAG	624		
Leu Lys Tyr Trp Leu Tyr Tyr Leu His Pro Val Leu Gln Arg Gln Gln			
195	200	205	
CTG GAC TAT GGC ATC TAT GTT ATC AAC CAG GCG GGA GAC ACT ATA TTC	672		
Leu Asp Tyr Gly Ile Tyr Val Ile Asn Gln Ala Gly Asp Thr Ile Phe			
210	215	220	

- 31 -

AAT CGT GCT AAG CTC CTC AAT GTT GGC TTT CAA GAA GCC TTG AAG GAC 720  
 Asn Arg Ala Lys Leu Leu Asn Val Gly Phe Gln Glu Ala Leu Lys Asp  
 225 230 235

TAT GAC TAC ACC TGC TTT GTG TTT AGT GAC GTG GAC CTC ATT CCA ATG 768  
 Tyr Asp Tyr Thr Cys Phe Val Phe Ser Asp Val Asp Leu Ile Pro Met  
 240 245 250

AAT GAC CAT AAT GCG TAC AGG TGT TTT TCA CAG CCA CGG CAC ATT TCC 816  
 Asn Asp His Asn Ala Tyr Arg Cys Phe Ser Gln Pro Arg His Ile Ser  
 255 260 265 270

GTT GCA ATG GAT AAG TTT GGA TTC AGC CTA CCT TAT GTT CAG TAT TTT 864  
 Val Ala Met Asp Lys Phe Gly Phe Ser Leu Pro Tyr Val Gln Tyr Phe  
 275 280 285

GGA GGT GTC TCT GCT CTA AGT AAA CAA CAG TTT CTA ACC ATC AAT GGA 912  
 Gly Gly Val Ser Ala Leu Ser Lys Gln Gln Phe Leu Thr Ile Asn Gly  
 290 295 300

TTT CCT AAT AAT TAT TGG GGC TGG GGA GGA GAA GAT GAT GAC ATT TTT 960  
 Phe Pro Asn Asn Tyr Trp Gly Trp Gly Gly Glu Asp Asp Asp Ile Phe  
 305 310 315

AAC AGA TTA GTT TTT AGA GGC ATG TCT ATA TCT CGC CCA AAT GCT GTG 1008  
 Asn Arg Leu Val Phe Arg Gly Met Ser Ile Ser Arg Pro Asn Ala Val  
 320 325 330

GTC GGG AGG TGT CGC ATG ATC CGC CAC TCA AGA GAC AAG AAA AAT GAA 1056  
 Val Gly Arg Cys Arg Met Ile Arg His Ser Arg Asp Lys Lys Asn Glu  
 335 340 345 350

CCC AAT CCT CAG AGG TTT GAC CGA ATT GCA CAC ACA AAG GAG ACA ATG 1104  
 Pro Asn Pro Gln Arg Phe Asp Arg Ile Ala His Thr Lys Glu Thr Met  
 355 360 365

- 32 -

CTC TCT GAT GGT TTG AAC TCA CTC ACC TAC CAG GTG CTG GAT GTA CAG 1152  
Leu Ser Asp Gly Leu Asn Ser Leu Thr Tyr Gln Val Leu Asp Val Gln

370 375 380

AGA TAC CCA TTG TAT ACC CAA ATC ACA GTG GAC ATC GGG ACA CCG AGC 1200  
Arg Tyr Pro Leu Tyr Thr Gln Ile Thr Val Asp Ile Gly Thr Pro Ser  
385 390 395

TAGGACTTTT GGTACAGGTA AAGACTGAAT TCATCGATAT CTAGATCTCG AGCTCGCGAA 1260

AGCTT 1265

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 398 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Arg Leu Arg Glu Pro Leu Leu Ser Gly Ser Ala Ala Met Pro Gly  
1 5 10 15

Ala Ser Leu Gln Arg Ala Cys Arg Leu Leu Val Ala Val Cys Ala Leu  
20 25 30

His Leu Gly Val Thr Leu Val Tyr Tyr Leu Ala Gly Arg Asp Leu Ser  
35 40 45

Arg Leu Pro Gln Leu Val Gly Val Ser Thr Pro Leu Gln Gly Gly Ser  
50 55 60

- 33 -

Asn Ser Ala Ala Ala Ile Gly Gln Ser Ser Gly Glu Leu Arg Thr Gly  
65 70 75 80

Gly Ala Arg Pro Pro Pro Pro Leu Gly Ala Ser Ser Gln Pro Arg Pro  
85 90 95

Gly Gly Asp Ser Ser Pro Val Val Asp Ser Gly Pro Gly Pro Ala Ser  
100 105 110

Asn Leu Thr Ser Val Pro Val Pro His Thr Thr Ala Leu Ser Leu Pro  
115 120 125

Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro Met Leu Ile Glu  
130 135 140

Phe Asn Met Pro Val Asp Leu Glu Leu Val Ala Lys Gln Asn Pro Asn  
145 150 155 160

Val Lys Met Gly Gly Arg Tyr Ala Pro Arg Asp Cys Val Ser Pro His  
165 170 175

Lys Val Ala Ile Ile Ile Pro Phe Arg Asn Arg Gln Glu His Leu Lys  
180 185 190

Tyr Trp Leu Tyr Tyr Leu His Pro Val Leu Gln Arg Gln Gln Leu Asp  
195 200 205

Tyr Gly Ile Tyr Val Ile Asn Gln Ala Gly Asp Thr Ile Phe Asn Arg  
210 215 220

Ala Lys Leu Leu Asn Val Gly Phe Gln Glu Ala Leu Lys Asp Tyr Asp  
225 230 235 240

Tyr Thr Cys Phe Val Phe Ser Asp Val Asp Leu Ile Pro Met Asn Asp  
245 250 255

- 34 -

His Asn Ala Tyr Arg Cys Phe Ser Gln Pro Arg His Ile Ser Val Ala  
260 265 270

Met Asp Lys Phe Gly Phe Ser Leu Pro Tyr Val Gln Tyr Phe Gly Gly  
275 280 285

Val Ser Ala Leu Ser Lys Gln Gln Phe Leu Thr Ile Asn Gly Phe Pro  
290 295 300

Asn Asn Tyr Trp Gly Trp Gly Gly Glu Asp Asp Asp Ile Phe Asn Arg  
305 310 315 320

Leu Val Phe Arg Gly Met Ser Ile Ser Arg Pro Asn Ala Val Val Gly  
325 330 335

Arg Cys Arg Met Ile Arg His Ser Arg Asp Lys Lys Asn Glu Pro Asn  
340 345 350

Pro Gln Arg Phe Asp Arg Ile Ala His Thr Lys Glu Thr Met Leu Ser  
355 360 365

Asp Gly Leu Asn Ser Leu Thr Tyr Gln Val Leu Asp Val Gln Arg Tyr  
370 375 380

Pro Leu Tyr Thr Gln Ile Thr Val Asp Ile Gly Thr Pro Ser  
385 390 395

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1246 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- 35 -

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

(B) STRAIN: E. coli DH5alpha

(vii) IMMEDIATE SOURCE:

(B) CLONE: pSIA2

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 15..1232

(D) OTHER INFORMATION: /product= "full-length  
sialyltransferase (EC 2.4.99.1)"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CTGCAGAATT CAAA ATG ATT CAC ACC AAC CTG AAG AAA AAG TTC AGC TGC 50  
Met Ile His Thr Asn Leu Lys Lys Lys Phe Ser Cys  
1 5 10

TGC GTC CTG GTC TTT CTT CTG TTT GCA GTC ATC TGT GTG TGG AAG GAA 98  
Cys Val Leu Val Phe Leu Leu Phe Ala Val Ile Cys Val Trp Lys Glu  
15 20 25

AAG AAG AAA GGG AGT TAC TAT GAT TCC TTT AAA TTG CAA ACC AAG GAA 146  
Lys Lys Lys Gly Ser Tyr Tyr Asp Ser Phe Lys Leu Gln Thr Lys Glu  
30 35 40

TTC CAG GTG TTA AAG AGT CTG GGG AAA TTG GCC ATG GGG TCT GAT TCC 194  
Phe Gln Val Leu Lys Ser Leu Gly Lys Leu Ala Met Gly Ser Asp Ser  
45 50 55 60

CAG TCT GTA TCC TCA AGC AGC ACC CAG GAC CCC CAC AGG GGC CGC CAG 242  
Gln Ser Val Ser Ser Ser Thr Gln Asp Pro His Arg Gly Arg Gln  
65 70 75

- 36 -

ACC CTC GGC AGT CTC AGA GGC CTA GCC AAG GCC AAA CCA GAG GCC TCC	290		
Thr Leu Gly Ser Leu Arg Gly Leu Ala Lys Ala Lys Pro Glu Ala Ser			
80	85	90	
TTC CAG GTG TGG AAC AAG GAC AGC TCT TCC AAA AAC CTT ATC CCT AGG	338		
Phe Gln Val Trp Asn Lys Asp Ser Ser Ser Lys Asn Leu Ile Pro Arg			
95	100	105	
CTG CAA AAG ATC TGG AAG AAT TAC CTA AGC ATG AAC AAG TAC AAA GTG	386		
Leu Gln Lys Ile Trp Lys Asn Tyr Leu Ser Met Asn Lys Tyr Lys Val			
110	115	120	
TCC TAC AAG GGG CCA GGA CCA GGC ATC AAG TTC AGT GCA GAG GCC CTG	434		
Ser Tyr Lys Gly Pro Gly Pro Gly Ile Lys Phe Ser Ala Glu Ala Leu			
125	130	135	140
CGC TGC CAC CTC CGG GAC CAT GTG AAT GTA TCC ATG GTA GAG GTC ACA	482		
Arg Cys His Leu Arg Asp His Val Asn Val Ser Met Val Glu Val Thr			
145	150	155	
GAT TTT CCC TTC AAT ACC TCT GAA TGG GAG GGT TAT CTG CCC AAG GAG	530		
Asp Phe Pro Phe Asn Thr Ser Glu Trp Glu Gly Tyr Leu Pro Lys Glu			
160	165	170	
AGC ATT AGG ACC AAG GCT GGG CCT TGG GGC AGG TGT GCT GTT GTG TCG	578		
Ser Ile Arg Thr Lys Ala Gly Pro Trp Gly Arg Cys Ala Val Val Ser			
175	180	185	
TCA GCG GGA TCT CTG AAG TCC TCC CAA CTA GGC AGA GAA ATC GAT GAT	626		
Ser Ala Gly Ser Leu Lys Ser Ser Gln Leu Gly Arg Glu Ile Asp Asp			
190	195	200	
CAT GAC GCA GTC CTG AGG TTT AAT GGG GCA CCC ACA AAC GCC AAG TTC CAA	674		
His Asp Ala Val Leu Arg Phe Asn Gly Ala Pro Thr Ala Asn Phe Gln			
205	210	215	220

- 37 -

CAA GAT GTG GGC ACA AAA ACT ACC ATT CGC CTG ATG AAC TCT CAG TTG	722		
Gln Asp Val Gly Thr Lys Thr Thr Ile Arg Leu Met Asn Ser Gln Leu			
225	230	235	
GTT ACC ACA GAG AAG CGC TTC CTC AAA GAC AGT TTG TAC AAT GAA GGA	770		
Val Thr Thr Glu Lys Arg Phe Leu Lys Asp Ser Leu Tyr Asn Glu Gly			
240	245	250	
ATC CTA ATT GTA TGG GAC CCA TCT GTA TAC CAC TCA GAT ATC CCA AAG	818		
Ile Leu Ile Val Trp Asp Pro Ser Val Tyr His Ser Asp Ile Pro Lys			
255	260	265	
TGG TAC CAG AAT CCG GAT TAT AAT TTC TTT AAC AAC TAC AAG ACT TAT	866		
Trp Tyr Gln Asn Pro Asp Tyr Asn Phe Phe Asn Asn Tyr Lys Thr Tyr			
270	275	280	
CGT AAG CTG CAC CCC AAT CAG CCC TTT TAC ATC CTC AAG CCC CAG ATG	914		
Arg Lys Leu His Pro Asn Gln Pro Phe Tyr Ile Leu Lys Pro Gln Met			
285	290	295	300
CCT TGG GAG CTA TGG GAC ATT CTT CAA GAA ATC TCC CCA GAA GAG ATT	962		
Pro Trp Glu Leu Trp Asp Ile Leu Gln Glu Ile Ser Pro Glu Glu Ile			
305	310	315	
CAG CCA AAC CCC CCA TCC TCT GGG ATG CTT GGT ATC ATC ATC ATG ATG	1010		
Gln Pro Asn Pro Pro Ser Ser Gly Met Leu Gly Ile Ile Ile Met Met			
320	325	330	
ACG CTG TGT GAC CAG GTG GAT ATT TAT GAG TTC CTC CCA TCC AAG CGC	1058		
Thr Leu Cys Asp Gln Val Asp Ile Tyr Glu Phe Leu Pro Ser Lys Arg			
335	340	345	
AAG ACT GAC GTG TGC TAC TAC CAG AAG TTC TTC GAT AGT GCC TGC	1106		
Lys Thr Asp Val Cys Tyr Tyr Gln Lys Phe Phe Asp Ser Ala Cys			
350	355	360	

- 38 -

ACG ATG GGT GCC TAC CAC CCG CTG CTC TAT GAG AAG AAT TTG GTG AAG 1154

Thr Met Gly Ala Tyr His Pro Leu Leu Tyr Glu Lys Asn Leu Val Lys

365 370 375 380

CAT CTC AAC CAG GGC ACA GAT GAG GAC ATC TAC CTG CTT GGA AAA GCC 1202

His Leu Asn Gln Gly Thr Asp Glu Asp Ile Tyr Leu Leu Gly Lys Ala

385 390 395

ACA CTG CCT GGC TTC CGG ACC ATT CAC TGC TAAGCACAGG ATCC 1246

Thr Leu Pro Gly Phe Arg Thr Ile His Cys

400 405

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 406 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met Ile His Thr Asn Leu Lys Lys Lys Phe Ser Cys Cys Val Leu Val

1 5 10 15

Phe Leu Leu Phe Ala Val Ile Cys Val Trp Lys Glu Lys Lys Gly

20 25 30

Ser Tyr Tyr Asp Ser Phe Lys Leu Gln Thr Lys Glu Phe Gln Val Leu

35 40 45

Lys Ser Leu Gly Lys Leu Ala Met Gly Ser Asp Ser Gln Ser Val Ser

50 55 60

- 39 -

Ser Ser Ser Thr Gln Asp Pro His Arg Gly Arg Gln Thr Leu Gly Ser  
65 70 75 80

Leu Arg Gly Leu Ala Lys Ala Lys Pro Glu Ala Ser Phe Gln Val Trp  
85 90 95

Asn Lys Asp Ser Ser Lys Asn Leu Ile Pro Arg Leu Gln Lys Ile  
100 105 110

Trp Lys Asn Tyr Leu Ser Met Asn Lys Tyr Lys Val Ser Tyr Lys Gly  
115 120 125

Pro Gly Pro Gly Ile Lys Phe Ser Ala Glu Ala Leu Arg Cys His Leu  
130 135 140

Arg Asp His Val Asn Val Ser Met Val Glu Val Thr Asp Phe Pro Phe  
145 150 155 160

Asn Thr Ser Glu Trp Glu Gly Tyr Leu Pro Lys Glu Ser Ile Arg Thr  
165 170 175

Lys Ala Gly Pro Trp Gly Arg Cys Ala Val Val Ser Ser Ala Gly Ser  
180 185 190

Leu Lys Ser Ser Gln Leu Gly Arg Glu Ile Asp Asp His Asp Ala Val  
195 200 205

Leu Arg Phe Asn Gly Ala Pro Thr Ala Asn Phe Gln Gln Asp Val Gly  
210 215 220

Thr Lys Thr Thr Ile Arg Leu Met Asn Ser Gln Leu Val Thr Thr Glu  
225 230 235 240

Lys Arg Phe Leu Lys Asp Ser Leu Tyr Asn Glu Gly Ile Leu Ile Val  
245 250 255

- 40 -

Trp Asp Pro Ser Val Tyr His Ser Asp Ile Pro Lys Trp Tyr Gln Asn  
260 265 270

Pro Asp Tyr Asn Phe Phe Asn Asn Tyr Lys Thr Tyr Arg Lys Leu His  
275 280 285

Pro Asn Gln Pro Phe Tyr Ile Leu Lys Pro Gln Met Pro Trp Glu Leu  
290 295 300

Trp Asp Ile Leu Gln Glu Ile Ser Pro Glu Glu Ile Gln Pro Asn Pro  
305 310 315 320

Pro Ser Ser Gly Met Leu Gly Ile Ile Ile Met Met Thr Leu Cys Asp  
325 330 335

Gln Val Asp Ile Tyr Glu Phe Leu Pro Ser Lys Arg Lys Thr Asp Val  
340 345 350

Cys Tyr Tyr Tyr Gln Lys Phe Phe Asp Ser Ala Cys Thr Met Gly Ala  
355 360 365

Tyr His Pro Leu Leu Tyr Glu Lys Asn Leu Val Lys His Leu Asn Gln  
370 375 380

Gly Thr Asp Glu Asp Ile Tyr Leu Leu Gly Lys Ala Thr Leu Pro Gly  
385 390 395 400

Phe Arg Thr Ile His Cys  
405

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2304 base pairs
- (B) TYPE: nucleic acid

- 41 -

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

(B) STRAIN: E. coli DH5alpha

(vii) IMMEDIATE SOURCE:

(B) CLONE: YEPGSTa

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..2301

(D) OTHER INFORMATION: /product=

"galactosyltransferase-sialyltransferase hybrid  
protein"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

ATG AGG CTT CGG GAG CCG CTC CTG AGC GGC AGC GCC GCG ATG CCA GGC 48  
Met Arg Leu Arg Glu Pro Leu Leu Ser Gly Ser Ala Ala Met Pro Gly  
1 5 10 15

GCG TCC CTA CAG CGG GCC TGC CGC CTG CTC GTG GCC GTC TGC GCT CTG 96  
Ala Ser Leu Gln Arg Ala Cys Arg Leu Leu Val Ala Val Cys Ala Leu  
20 25 30

CAC CTT GGC GTC ACC CTC GTT TAC TAC CTG GCT GGC CGC GAC CTG AGC 144  
His Leu Gly Val Thr Leu Val Tyr Tyr Leu Ala Gly Arg Asp Leu Ser  
35 40 45

CGC CTG CCC CAA CTG GTC GGA GTC TCC ACA CCG CTG CAG GGC GGC TCG 192  
Arg Leu Pro Gln Leu Val Gly Val Ser Thr Pro Leu Gln Gly Gly Ser  
50 55 60

- 42 -

AAC AGT GCC GCC ATC GGG CAG TCC TCC GGG GAG CTC CGG ACC GGA	240		
Asn Ser Ala Ala Ala Ile Gly Gln Ser Ser Gly Glu Leu Arg Thr Gly			
65	70	75	80
GGG GCC CGG CCG CCT CCT CTA GGC GCC TCC TCC CAG CCG CGC CCG	288		
Gly Ala Arg Pro Pro Pro Pro Leu Gly Ala Ser Ser Gln Pro Arg Pro			
85	90	95	
GGT GGC GAC TCC AGC CCA GTC GTG GAT TCT GGC CCT GGC CCC GCT AGC	336		
Gly Gly Asp Ser Ser Pro Val Val Asp Ser Gly Pro Gly Pro Ala Ser			
100	105	110	
AAC TTG ACC TCG GTC CCA GTG CCC CAC ACC ACC GCA CTG TCG CTG CCC	384		
Asn Leu Thr Ser Val Pro Val Pro His Thr Thr Ala Leu Ser Leu Pro			
115	120	125	
GCC TGC CCT GAG GAG TCC CCG CTG CTT GTG GGC CCC ATG CTG ATT GAG	432		
Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro Met Leu Ile Glu			
130	135	140	
TTT AAC ATG CCT GTG GAC CTG GAG CTC GTG GCA AAG CAG AAC CCA AAT	480		
Phe Asn Met Pro Val Asp Leu Glu Leu Val Ala Lys Gln Asn Pro Asn			
145	150	155	160
GTG AAG ATG GGC GGC CGC TAT GCC CCC AGG GAC TGC GTC TCT CCT CAC	528		
Val Lys Met Gly Gly Arg Tyr Ala Pro Arg Asp Cys Val Ser Pro His			
165	170	175	
AAG GTG GCC ATC ATC ATT CCA TTC CGC AAC CGG CAG GAG CAC CTC AAG	576		
Lys Val Ala Ile Ile Ile Pro Phe Arg Asn Arg Gln Glu His Leu Lys			
180	185	190	
TAC TGG CTA TAT TAT TTG CAC CCA GTC CTG CAG CGC CAG CAG CTG GAC	624		
Tyr Trp Leu Tyr Tyr Leu His Pro Val Leu Gln Arg Gln Gln Leu Asp			
195	200	205	

- 43 -

TAT GGC ATC TAT GTT ATC AAC CAG GCG GGA GAC ACT ATA TTC AAT CGT 672  
 Tyr Gly Ile Tyr Val Ile Asn Gln Ala Gly Asp Thr Ile Phe Asn Arg  
 210 215 220

GCT AAG CTC CTC AAT GTT GGC TTT CAA GAA GCC TTG AAG GAC TAT GAC 720  
 Ala Lys Leu Leu Asn Val Gly Phe Gln Glu Ala Leu Lys Asp Tyr Asp  
 225 230 235 240

TAC ACC TGC TTT GTG TTT AGT GAC GTG GAC CTC ATT CCA ATG AAT GAC 768  
 Tyr Thr Cys Phe Val Phe Ser Asp Val Asp Leu Ile Pro Met Asn Asp  
 245 250 255

CAT AAT GCG TAC AGG TGT TTT TCA CAG CCA CGG CAC ATT TCC GTT GCA 816  
 His Asn Ala Tyr Arg Cys Phe Ser Gln Pro Arg His Ile Ser Val Ala  
 260 265 270

ATG GAT AAG TTT GGA TTC AGC CTA CCT TAT GTT CAG TAT TTT GGA GGT 864  
 Met Asp Lys Phe Gly Phe Ser Leu Pro Tyr Val Gln Tyr Phe Gly Gly  
 275 280 285

GTC TCT GCT CTA AGT AAA CAA CAG TTT CTA ACC ATC AAT GGA TTT CCT 912  
 Val Ser Ala Leu Ser Lys Gln Gln Phe Leu Thr Ile Asn Gly Phe Pro  
 290 295 300

AAT AAT TAT TGG GGC TGG GGA GGA GAA GAT GAT GAC ATT TTT AAC AGA 960  
 Asn Asn Tyr Trp Gly Trp Gly Gly Glu Asp Asp Asp Ile Phe Asn Arg  
 305 310 315 320

TTA GTT TTT AGA GGC ATG TCT ATA TCT CGC CCA AAT GCT GTG GTC GGG 1008  
 Leu Val Phe Arg Gly Met Ser Ile Ser Arg Pro Asn Ala Val Val Gly  
 325 330 335

AGG TGT CGC ATG ATC CGC CAC TCA AGA GAC AAG AAA AAT GAA CCC AAT 1056  
 Arg Cys Arg Met Ile Arg His Ser Arg Asp Lys Lys Asn Glu Pro Asn  
 340 345 350

- 44 -

CCT CAG AGG TTT GAC CGA ATT GCA CAC ACA AAG GAG ACA ATG CTC TCT 1104  
Pro Gln Arg Phe Asp Arg Ile Ala His Thr Lys Glu Thr Met Leu Ser  
355 360 365

GAT GGT TTG AAC TCA CTC ACC TAC CAG GTG CTG GAT GTA CAG AGA TAC 1152  
Asp Gly Leu Asn Ser Leu Thr Tyr Gln Val Leu Asp Val Gln Arg Tyr  
370 375 380

CCA TTG TAT ACC CAA ATC ACA GTG GAC ATC GGG ACA CGA GCT GGG ATC 1200  
Pro Leu Tyr Thr Gln Ile Thr Val Asp Ile Gly Thr Arg Ala Gly Ile  
385 390 395 400

CGT CGA CCT GCA GAA TTC CAG GTG TTA AAG AGT CTG GGG AAA TTG GCC 1248  
Arg Arg Pro Ala Glu Phe Gln Val Leu Lys Ser Leu Gly Lys Leu Ala  
405 410 415

ATG GGG TCT GAT TCC CAG TCT GTA TCC TCA AGC AGC ACC CAG GAC CCC 1296  
Met Gly Ser Asp Ser Gln Ser Val Ser Ser Ser Thr Gln Asp Pro  
420 425 430

CAC AGG GGC CGC CAG ACC CTC GGC AGT CTC AGA GGC CTA GCC AAG GCC 1344  
His Arg Gly Arg Gln Thr Leu Gly Ser Leu Arg Gly Leu Ala Lys Ala  
435 440 445

AAA CCA GAG GCC TCC TTC CAG GTG TGG AAC AAG GAC AGC TCT TCC AAA 1392  
Lys Pro Glu Ala Ser Phe Gln Val Trp Asn Lys Asp Ser Ser Lys  
450 455 460

AAC CTT ATC CCT AGG CTG CAA AAG ATC TGG AAG AAT TAC CTA AGC ATG 1440  
Asn Leu Ile Pro Arg Leu Gln Lys Ile Trp Lys Asn Tyr Leu Ser Met  
465 470 475 480

AAC AAG TAC AAA GTG TCC TAC AAG GGG CCA GGA CCA GGC ATC AAG TTC 1488  
Asn Lys Tyr Lys Val Ser Tyr Lys Gly Pro Gly Pro Gly Ile Lys Phe  
485 490 495

- 45 -

AGT GCA GAG GCC CTG CGC TGC CAC CTC CGG GAC CAT GTG AAT GTA TCC 1536  
 Ser Ala Glu Ala Leu Arg Cys His Leu Arg Asp His Val Asn Val Ser  
 500 505 510

ATG GTA GAG GTC ACA GAT TTT CCC TTC AAT ACC TCT GAA TGG GAG GGT 1584  
 Met Val Glu Val Thr Asp Phe Pro Phe Asn Thr Ser Glu Trp Glu Gly  
 515 520 525

TAT CTG CCC AAG GAG AGC ATT AGG ACC AAG GCT GGG CCT TGG GGC AGG 1632  
 Tyr Leu Pro Lys Glu Ser Ile Arg Thr Lys Ala Gly Pro Trp Gly Arg  
 530 535 540

TGT GCT GTT GTG TCG TCA GCG GGA TCT CTG AAG TCC TCC CAA CTA GGC 1680  
 Cys Ala Val Val Ser Ser Ala Gly Ser Leu Lys Ser Ser Gln Leu Gly  
 545 550 555 560

AGA GAA ATC GAT GAT CAT GAC GCA GTC CTG AGG TTT AAT GGG GCA CCC 1728  
 Arg Glu Ile Asp Asp His Asp Ala Val Leu Arg Phe Asn Gly Ala Pro  
 565 570 575

ACA GCC AAC TTC CAA CAA GAT GTG GGC ACA AAA ACT ACC ATT CGC CTG 1776  
 Thr Ala Asn Phe Gln Gln Asp Val Gly Thr Lys Thr Thr Ile Arg Leu  
 580 585 590

ATG AAC TCT CAG TTG GTT ACC ACA GAG AAG CGC TTC CTC AAA GAC AGT 1824  
 Met Asn Ser Gln Leu Val Thr Thr Glu Lys Arg Phe Leu Lys Asp Ser  
 595 600 605

TTG TAC AAT GAA GGA ATC CTA ATT GTA TGG GAC CCA TCT GTA TAC CAC 1872  
 Leu Tyr Asn Glu Gly Ile Leu Ile Val Trp Asp Pro Ser Val Tyr His  
 610 615 620

TCA GAT ATC CCA AAG TGG TAC CAG AAT CCG GAT TAT AAT TTC TTT AAC 1920  
 Ser Asp Ile Pro Lys Trp Tyr Gln Asn Pro Asp Tyr Asn Phe Phe Asn  
 625 630 635 640

- 46 -

AAC TAC AAG ACT TAT CGT AAG CTG CAC CCC AAT CAG CCC TTT TAC ATC 1968  
Asn Tyr Lys Thr Tyr Arg Lys Leu His Pro Asn Gln Pro Phe Tyr Ile  
645 650 655

CTC AAG CCC CAG ATG CCT TGG GAG CTA TGG GAC ATT CTT CAA GAA ATC 2016  
Leu Lys Pro Gln Met Pro Trp Glu Leu Trp Asp Ile Leu Gln Glu Ile  
660 665 670

TCC CCA GAA GAG ATT CAG CCA AAC CCC CCA TCC TCT GGG ATG CTT GGT 2064  
Ser Pro Glu Glu Ile Gln Pro Asn Pro Pro Ser Ser Gly Met Leu Gly  
675 680 685

ATC ATC ATC ATG ATG ACG CTG TGT GAC CAG GTG GAT ATT TAT GAG TTC 2112  
Ile Ile Ile Met Met Thr Leu Cys Asp Gln Val Asp Ile Tyr Glu Phe  
690 695 700

CTC CCA TCC AAG CGC AAG ACT GAC GTG TGC TAC TAC CAG AAG TTC 2160  
Leu Pro Ser Lys Arg Lys Thr Asp Val Cys Tyr Tyr Tyr Gln Lys Phe  
705 710 715 720

TTC GAT AGT GCC TGC ACG ATG GGT GCC TAC CAC CCG CTG CTC TAT GAG 2208  
Phe Asp Ser Ala Cys Thr Met Gly Ala Tyr His Pro Leu Leu Tyr Glu  
725 730 735

AAG AAT TTG GTG AAG CAT CTC AAC CAG GGC ACA GAT GAG GAC ATC TAC 2256  
Lys Asn Leu Val Lys His Leu Asn Gln Gly Thr Asp Glu Asp Ile Tyr  
740 745 750

CTG CTT GGA AAA GCC ACA CTG CCT GGC TTC CGG ACC ATT CAC TGC 2301  
Leu Leu Gly Lys Ala Thr Leu Pro Gly Phe Arg Thr Ile His Cys  
755 760 765

TAA 2304

- 47 -

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 767 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Arg Leu Arg Glu Pro Leu Leu Ser Gly Ser Ala Ala Met Pro Gly  
1 5 10 15

Ala Ser Leu Gln Arg Ala Cys Arg Leu Leu Val Ala Val Cys Ala Leu  
20 25 30

His Leu Gly Val Thr Leu Val Tyr Tyr Leu Ala Gly Arg Asp Leu Ser  
35 40 45

Arg Leu Pro Gln Leu Val Gly Val Ser Thr Pro Leu Gln Gly Gly Ser  
50 55 60

Asn Ser Ala Ala Ala Ile Gly Gln Ser Ser Gly Glu Leu Arg Thr Gly  
65 70 75 80

Gly Ala Arg Pro Pro Pro Leu Gly Ala Ser Ser Gln Pro Arg Pro  
85 90 95

Gly Gly Asp Ser Ser Pro Val Val Asp Ser Gly Pro Gly Pro Ala Ser  
100 105 110

Asn Leu Thr Ser Val Pro Val Pro His Thr Thr Ala Leu Ser Leu Pro  
115 120 125

- 48 -

Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro Met Leu Ile Glu  
130 135 140

Phe Asn Met Pro Val Asp Leu Glu Leu Val Ala Lys Gln Asn Pro Asn  
145 150 155 160

Val Lys Met Gly Gly Arg Tyr Ala Pro Arg Asp Cys Val Ser Pro His  
165 170 175

Lys Val Ala Ile Ile Ile Pro Phe Arg Asn Arg Gln Glu His Leu Lys  
180 185 190

Tyr Trp Leu Tyr Tyr Leu His Pro Val Leu Gln Arg Gln Gln Leu Asp  
195 200 205

Tyr Gly Ile Tyr Val Ile Asn Gln Ala Gly Asp Thr Ile Phe Asn Arg  
210 215 220

Ala Lys Leu Leu Asn Val Gly Phe Gln Glu Ala Leu Lys Asp Tyr Asp  
225 230 235 240

Tyr Thr Cys Phe Val Phe Ser Asp Val Asp Leu Ile Pro Met Asn Asp  
245 250 255

His Asn Ala Tyr Arg Cys Phe Ser Gln Pro Arg His Ile Ser Val Ala  
260 265 270

Met Asp Lys Phe Gly Phe Ser Leu Pro Tyr Val Gln Tyr Phe Gly Gly  
275 280 285

Val Ser Ala Leu Ser Lys Gln Gln Phe Leu Thr Ile Asn Gly Phe Pro  
290 295 300

Asn Asn Tyr Trp Gly Trp Gly Gly Glu Asp Asp Asp Ile Phe Asn Arg  
305 310 315 320

- 49 -

Leu Val Phe Arg Gly Met Ser Ile Ser Arg Pro Asn Ala Val Val Gly  
325 330 335

Arg Cys Arg Met Ile Arg His Ser Arg Asp Lys Lys Asn Glu Pro Asn  
340 345 350

Pro Gln Arg Phe Asp Arg Ile Ala His Thr Lys Glu Thr Met Leu Ser  
355 360 365

Asp Gly Leu Asn Ser Leu Thr Tyr Gln Val Leu Asp Val Gln Arg Tyr  
370 375 380

Pro Leu Tyr Thr Gln Ile Thr Val Asp Ile Gly Thr Arg Ala Gly Ile  
385 390 395 400

Arg Arg Pro Ala Glu Phe Gln Val Leu Lys Ser Leu Gly Lys Leu Ala  
405 410 415

Met Gly Ser Asp Ser Gln Ser Val Ser Ser Ser Thr Gln Asp Pro  
420 425 430

His Arg Gly Arg Gln Thr Leu Gly Ser Leu Arg Gly Leu Ala Lys Ala  
435 440 445

Lys Pro Glu Ala Ser Phe Gln Val Trp Asn Lys Asp Ser Ser Ser Lys  
450 455 460

Asn Leu Ile Pro Arg Leu Gln Lys Ile Trp Lys Asn Tyr Leu Ser Met  
465 470 475 480

Asn Lys Tyr Lys Val Ser Tyr Lys Gly Pro Gly Pro Gly Ile Lys Phe  
485 490 495

Ser Ala Glu Ala Leu Arg Cys His Leu Arg Asp His Val Asn Val Ser  
500 505 510

- 50 -

Met Val Glu Val Thr Asp Phe Pro Phe Asn Thr Ser Glu Trp Glu Gly  
515 520 525

Tyr Leu Pro Lys Glu Ser Ile Arg Thr Lys Ala Gly Pro Trp Gly Arg  
530 535 540

Cys Ala Val Val Ser Ser Ala Gly Ser Leu Lys Ser Ser Gln Leu Gly  
545 550 555 560

Arg Glu Ile Asp Asp His Asp Ala Val Leu Arg Phe Asn Gly Ala Pro  
565 570 575

Thr Ala Asn Phe Gln Gln Asp Val Gly Thr Lys Thr Thr Ile Arg Leu  
580 585 590

Met Asn Ser Gln Leu Val Thr Thr Glu Lys Arg Phe Leu Lys Asp Ser  
595 600 605

Leu Tyr Asn Glu Gly Ile Leu Ile Val Trp Asp Pro Ser Val Tyr His  
610 615 620

Ser Asp Ile Pro Lys Trp Tyr Gln Asn Pro Asp Tyr Asn Phe Phe Asn  
625 630 635 640

Asn Tyr Lys Thr Tyr Arg Lys Leu His Pro Asn Gln Pro Phe Tyr Ile  
645 650 655

Leu Lys Pro Gln Met Pro Trp Glu Leu Trp Asp Ile Leu Gln Glu Ile  
660 665 670

Ser Pro Glu Glu Ile Gln Pro Asn Pro Pro Ser Ser Gly Met Leu Gly  
675 680 685

Ile Ile Ile Met Met Thr Leu Cys Asp Gln Val Asp Ile Tyr Glu Phe  
690 695 700

- 51 -

Leu Pro Ser Lys Arg Lys Thr Asp Val Cys Tyr Tyr Tyr Gln Lys Phe  
705 710 715 720

Phe Asp Ser Ala Cys Thr Met Gly Ala Tyr His Pro Leu Leu Tyr Glu  
725 730 735

Lys Asn Leu Val Lys His Leu Asn Gln Gly Thr Asp Glu Asp Ile Tyr  
740 745 750

Leu Leu Gly Lys Ala Thr Leu Pro Gly Phe Arg Thr Ile His Cys  
755 760 765

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2304 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (B) STRAIN: E. coli DH5alpha

(vii) IMMEDIATE SOURCE:

- (B) CLONE: YEPGSTb

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2301
- (D) OTHER INFORMATION: /product=  
"galactosyltransferase-sialyltransferase hybrid  
protein"

- 52 -

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

ATG	AGG	CTT	CGG	GAG	CCG	CTC	CTG	AGC	GGC	AGC	GCC	GCG	ATG	CCA	GGC	48
Met	Arg	Leu	Arg	Glu	Pro	Leu	Leu	Ser	Gly	Ser	Ala	Ala	Met	Pro	Gly	
1		5						10					15			
GCG	TCC	CTA	CAG	CGG	GCC	TGC	CGC	CTG	CTC	GTG	GCC	GTC	TGC	GCT	CTG	96
Ala	Ser	Leu	Gln	Arg	Ala	Cys	Arg	Leu	Leu	Val	Ala	Val	Cys	Ala	Leu	
	20					25							30			
CAC	CTT	GGC	GTC	ACC	CTC	GTT	TAC	TAC	CTG	GCT	GGC	CGC	GAC	CTG	AGC	144
His	Leu	Gly	Val	Thr	Leu	Val	Tyr	Tyr	Leu	Ala	Gly	Arg	Asp	Leu	Ser	
	35					40							45			
CGC	CTG	CCC	CAA	CTG	GTC	GGA	GTC	TCC	ACA	CCG	CTG	CAG	GGC	GGC	TCG	192
Arg	Leu	Pro	Gln	Leu	Val	Gly	Val	Ser	Thr	Pro	Leu	Gln	Gly	Gly	Ser	
	50					55						60				
AAC	AGT	GCC	GCC	ATC	GGG	CAG	TCC	TCC	GGG	GAG	CTC	CGG	ACC	GGA	240	
Asn	Ser	Ala	Ala	Ala	Ile	Gly	Gln	Ser	Ser	Gly	Glu	Leu	Arg	Thr	Gly	
	65				70				75				80			
GGG	GCC	CGG	CCG	CCG	CCT	CCT	CTA	GGC	GCC	TCC	TCC	CAG	CCG	CGC	CCG	288
Gly	Ala	Arg	Pro	Pro	Pro	Pro	Leu	Gly	Ala	Ser	Ser	Gln	Pro	Arg	Pro	
	85						90						95			
GGT	GGC	GAC	TCC	AGC	CCA	GTC	GTG	GAT	TCT	GGC	CCT	GGC	CCC	GCT	AGC	336
Gly	Gly	Asp	Ser	Ser	Pro	Val	Val	Asp	Ser	Gly	Pro	Gly	Pro	Ala	Ser	
	100					105							110			
AAC	TTG	ACC	TCG	GTC	CCA	GTG	CCC	CAC	ACC	ACC	GCA	CTG	TCG	CTG	CCC	384
Asn	Leu	Thr	Ser	Val	Pro	Val	Pro	His	Thr	Thr	Ala	Leu	Ser	Leu	Pro	
	115						120						125			

- 53 -

GCC TGC CCT GCT GAG GAG TCC CCG CTG CTT GTG GGC CCC ATG CTG ATT GAG	432		
Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro Met Leu Ile Glu			
130	135	140	
TTT AAC ATG CCT GTG GAC CTG GAG CTC GTG GCA AAG CAG AAC CCA AAT	480		
Phe Asn Met Pro Val Asp Leu Glu Leu Val Ala Lys Gln Asn Pro Asn			
145	150	155	160
GTG AAG ATG GGC GGC CGC TAT GCC CCC AGG GAC TGC GTC TCT CCT CAC	528		
Val Lys Met Gly Gly Arg Tyr Ala Pro Arg Asp Cys Val Ser Pro His			
165	170	175	
AAG GTG GCC ATC ATC ATT CCA TTC CGC AAC CGG CAG GAG CAC CTC AAG	576		
Lys Val Ala Ile Ile Ile Pro Phe Arg Asn Arg Gln Glu His Leu Lys			
180	185	190	
TAC TGG CTA TAT TAT TTG CAC CCA GTC CTG CAG CGC CAG CAG CTG GAC	624		
Tyr Trp Leu Tyr Tyr Leu His Pro Val Leu Gln Arg Gln Gln Leu Asp			
195	200	205	
TAT GGC ATC TAT GTT ATC AAC CAG GCG GGA GAC ACT ATA TTC AAT CGT	672		
Tyr Gly Ile Tyr Val Ile Asn Gln Ala Gly Asp Thr Ile Phe Asn Arg			
210	215	220	
GCT AAG CTC CTC AAT GTT GGC TTT CAA GAA GCC TTG AAG GAC TAT GAC	720		
Ala Lys Leu Leu Asn Val Gly Phe Gln Glu Ala Leu Lys Asp Tyr Asp			
225	230	235	240
TAC ACC TGC TTT GTG TTT AGT GAC GTG GAC CTC ATT CCA ATG AAT GAC	768		
Tyr Thr Cys Phe Val Phe Ser Asp Val Asp Leu Ile Pro Met Asn Asp			
245	250	255	
CAT AAT GCG TAC AGG TGT TTT TCA CAG CCA CGG CAC ATT TCC GTT GCA	816		
His Asn Ala Tyr Arg Cys Phe Ser Gln Pro Arg His Ile Ser Val Ala			
260	265	270	

- 54 -

ATG GAT AAG TTT GGA TTC AGC CTA CCT TAT GTT CAG TAT TTT GGA GGT	864	
Met Asp Lys Phe Gly Phe Ser Leu Pro Tyr Val Gln Tyr Phe Gly Gly		
275	280	285
GTC TCT GCT CTA AGT AAA CAA CAG TTT CTA ACC ATC AAT GGA TTT CCT	912	
Val Ser Ala Leu Ser Lys Gln Gln Phe Leu Thr Ile Asn Gly Phe Pro		
290	295	300
AAT AAT TAT TGG GGC TGG GGA GGA GAA GAT GAT GAC ATT TTT AAC AGA	960	
Asn Asn Tyr Trp Gly Trp Gly Gly Glu Asp Asp Asp Ile Phe Asn Arg		
305	310	315
320		
TTA GTT TTT AGA GGC ATG TCT ATA TCT CGC CCA AAT GCT GTG GTC GGG	1008	
Leu Val Phe Arg Gly Met Ser Ile Ser Arg Pro Asn Ala Val Val Gly		
325	330	335
AGG TGT CGC ATG ATC CGC CAC TCA AGA GAC AAG AAA AAT GAA CCC AAT	1056	
Arg Cys Arg Met Ile Arg His Ser Arg Asp Lys Lys Asn Glu Pro Asn		
340	345	350
CCT CAG AGG TTT GAC CGA ATT GCA CAC ACA AAG GAG ACA ATG CTC TCT	1104	
Pro Gln Arg Phe Asp Arg Ile Ala His Thr Lys Glu Thr Met Leu Ser		
355	360	365
GAT GGT TTG AAC TCA CTC ACC TAC CAG GTG CTG GAT GTA CAG AGA TAC	1152	
Asp Gly Leu Asn Ser Leu Thr Tyr Gln Val Leu Asp Val Gln Arg Tyr		
370	375	380
CCA TTG TAT ACC CAA ATC ACA GTG GAC ATC GGG ACA CGA GCT AGG ATC	1200	
Pro Leu Tyr Thr Gln Ile Thr Val Asp Ile Gly Thr Arg Ala Arg Ile		
385	390	395
400		
CGT CGA CCT GCA GAA TTC CAG GTG TTA AAG AGT CTG GGG AAA TTG GCC	1248	
Arg Arg Pro Ala Glu Phe Gln Val Leu Lys Ser Leu Gly Lys Leu Ala		
405	410	415

- 55 -

ATG GGG TCT GAT TCC CAG TCT GTA TCC TCA AGC AGC ACC CAG GAC CCC 1296

Met Gly Ser Asp Ser Gln Ser Val Ser Ser Ser Thr Gln Asp Pro

420 425 430

CAC AGG GGC CGC CAG ACC CTC GGC AGT CTC AGA GGC CTA GCC AAG GCC 1344

His Arg Gly Arg Gln Thr Leu Gly Ser Leu Arg Gly Leu Ala Lys Ala

435 440 445

AAA CCA GAG GCC TCC TTC CAG GTG TGG AAC AAG GAC AGC TCT TCC AAA 1392

Lys Pro Glu Ala Ser Phe Gln Val Trp Asn Lys Asp Ser Ser Lys

450 455 460

AAC CTT ATC CCT AGG CTG CAA AAG ATC TGG AAG AAT TAC CTA AGC ATG 1440

Asn Leu Ile Pro Arg Leu Gln Lys Ile Trp Lys Asn Tyr Leu Ser Met

465 470 475 480

AAC AAG TAC AAA GTG TCC TAC AAG GGG CCA GGA CCA GGC ATC AAG TTC 1488

Asn Lys Tyr Lys Val Ser Tyr Lys Gly Pro Gly Pro Gly Ile Lys Phe

485 490 495

AGT GCA GAG GCC CTG CGC TGC CAC CTC CGG GAC CAT GTG AAT GTA TCC 1536

Ser Ala Glu Ala Leu Arg Cys His Leu Arg Asp His Val Asn Val Ser

500 505 510

ATG GTA GAG GTC ACA GAT TTT CCC TTC AAT ACC TCT GAA TGG GAG GGT 1584

Met Val Glu Val Thr Asp Phe Pro Phe Asn Thr Ser Glu Trp Glu Gly

515 520 525

TAT CTG CCC AAG GAG AGC ATT AGG ACC AAG GCT GGG CCT TGG GGC AGG 1632

Tyr Leu Pro Lys Glu Ser Ile Arg Thr Lys Ala Gly Pro Trp Gly Arg

530 535 540

TGT GCT GTT GTG TCG TCA GCG GGA TCT CTG AAG TCC TCC CAA CTA GGC 1680

Cys Ala Val Val Ser Ser Ala Gly Ser Leu Lys Ser Ser Gln Leu Gly

545 550 555 560

- 56 -

AGA GAA ATC GAT GAT CAT GAC GCA GTC CTG AGG TTT AAT GGG GCA CCC 1728  
Arg Glu Ile Asp Asp His Asp Ala Val Leu Arg Phe Asn Gly Ala Pro  
565 570 575

ACA GCC AAC TTC CAA CAA GAT GTG GGC ACA AAA ACT ACC ATT CGC CTG 1776  
Thr Ala Asn Phe Gln Gln Asp Val Gly Thr Lys Thr Thr Ile Arg Leu  
580 585 590

ATG AAC TCT CAG TTG GTT ACC ACA GAG AAG CGC TTC CTC AAA GAC AGT 1824  
Met Asn Ser Gln Leu Val Thr Thr Glu Lys Arg Phe Leu Lys Asp Ser  
595 600 605

TTG TAC AAT GAA GGA ATC CTA ATT GTA TGG GAC CCA TCT GTA TAC CAC 1872  
Leu Tyr Asn Glu Gly Ile Leu Ile Val Trp Asp Pro Ser Val Tyr His  
610 615 620

TCA GAT ATC CCA AAG TGG TAC CAG AAT CCG GAT TAT AAT TTC TTT AAC 1920  
Ser Asp Ile Pro Lys Trp Tyr Gln Asn Pro Asp Tyr Asn Phe Phe Asn  
625 630 635 640

AAC TAC AAG ACT TAT CGT AAG CTG CAC CCC AAT CAG CCC TTT TAC ATC 1968  
Asn Tyr Lys Thr Tyr Arg Lys Leu His Pro Asn Gln Pro Phe Tyr Ile  
645 650 655

CTC AAG CCC CAG ATG CCT TGG GAG CTA TGG GAC ATT CTT CAA GAA ATC 2016  
Leu Lys Pro Gln Met Pro Trp Glu Leu Trp Asp Ile Leu Gln Glu Ile  
660 665 670

TCC CCA GAA GAG ATT CAG CCA AAC CCC CCA TCC TCT GGG ATG CTT GGT 2064  
Ser Pro Glu Glu Ile Gln Pro Asn Pro Pro Ser Ser Gly Met Leu Gly  
675 680 685

ATC ATC ATC ATG ATG ACG CTG TGT GAC CAG GTG GAT ATT TAT GAG TTC 2112  
Ile Ile Ile Met Met Thr Leu Cys Asp Gln Val Asp Ile Tyr Glu Phe  
690 695 700

- 57 -

CTC CCA TCC AAG CGC AAG ACT GAC GTG TGC TAC TAC CAG AAG TTC 2160

Leu Pro Ser Lys Arg Lys Thr Asp Val Cys Tyr Tyr Tyr Gln Lys Phe

705

710

715

720

TTC GAT AGT GCC TGC ACG ATG GGT GCC TAC CAC CCG CTG CTC TAT GAG 2208

Phe Asp Ser Ala Cys Thr Met Gly Ala Tyr His Pro Leu Leu Tyr Glu

725

730

735

AAG AAT TTG GTG AAG CAT CTC AAC CAG GGC ACA GAT GAG GAC ATC TAC 2256

Lys Asn Leu Val Lys His Leu Asn Gln Gly Thr Asp Glu Asp Ile Tyr

740

745

750

CTG CTT GGA AAA GCC ACA CTG CCT GGC TTC CCG ACC ATT CAC TGC 2301

Leu Leu Gly Lys Ala Thr Leu Pro Gly Phe Arg Thr Ile His Cys

755

760

765

TAA

2304

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 767 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Arg Leu Arg Glu Pro Leu Leu Ser Gly Ser Ala Ala Met Pro Gly

1

5

10

15

Ala Ser Leu Gln Arg Ala Cys Arg Leu Leu Val Ala Val Cys Ala Leu

20

25

30

- 58 -

His Leu Gly Val Thr Leu Val Tyr Tyr Leu Ala Gly Arg Asp Leu Ser

35 40 45

Arg Leu Pro Gln Leu Val Gly Val Ser Thr Pro Leu Gln Gly Gly Ser

50 55 60

Asn Ser Ala Ala Ala Ile Gly Gln Ser Ser Gly Glu Leu Arg Thr Gly

65 70 75 80

Gly Ala Arg Pro Pro Pro Pro Leu Gly Ala Ser Ser Gln Pro Arg Pro

85 90 95

Gly Gly Asp Ser Ser Pro Val Val Asp Ser Gly Pro Gly Pro Ala Ser

100 105 110

Asn Leu Thr Ser Val Pro Val Pro His Thr Thr Ala Leu Ser Leu Pro

115 120 125

Ala Cys Pro Glu Glu Ser Pro Leu Leu Val Gly Pro Met Leu Ile Glu

130 135 140

Phe Asn Met Pro Val Asp Leu Glu Leu Val Ala Lys Gln Asn Pro Asn

145 150 155 160

Val Lys Met Gly Gly Arg Tyr Ala Pro Arg Asp Cys Val Ser Pro His

165 170 175

Lys Val Ala Ile Ile Ile Pro Phe Arg Asn Arg Gln Glu His Leu Lys

180 185 190

Tyr Trp Leu Tyr Tyr Leu His Pro Val Leu Gln Arg Gln Gln Leu Asp

195 200 205

Tyr Gly Ile Tyr Val Ile Asn Gln Ala Gly Asp Thr Ile Phe Asn Arg

210 215 220

- 59 -

Ala Lys Leu Leu Asn Val Gly Phe Gln Glu Ala Leu Lys Asp Tyr Asp

225

230

235

240

Tyr Thr Cys Phe Val Phe Ser Asp Val Asp Leu Ile Pro Met Asn Asp

245

250

255

His Asn Ala Tyr Arg Cys Phe Ser Gln Pro Arg His Ile Ser Val Ala

260

265

270

Met Asp Lys Phe Gly Phe Ser Leu Pro Tyr Val Gln Tyr Phe Gly Gly

275

280

285

Val Ser Ala Leu Ser Lys Gln Gln Phe Leu Thr Ile Asn Gly Phe Pro

290

295

300

Asn Asn Tyr Trp Gly Trp Gly Gly Glu Asp Asp Asp Ile Phe Asn Arg

305

310

315

320

Leu Val Phe Arg Gly Met Ser Ile Ser Arg Pro Asn Ala Val Val Gly

325

330

335

Arg Cys Arg Met Ile Arg His Ser Arg Asp Lys Lys Asn Glu Pro Asn

340

345

350

Pro Gln Arg Phe Asp Arg Ile Ala His Thr Lys Glu Thr Met Leu Ser

355

360

365

Asp Gly Leu Asn Ser Leu Thr Tyr Gln Val Leu Asp Val Gln Arg Tyr

370

375

380

Pro Leu Tyr Thr Gln Ile Thr Val Asp Ile Gly Thr Arg Ala Arg Ile

385

390

395

400

Arg Arg Pro Ala Glu Phe Gln Val Leu Lys Ser Leu Gly Lys Leu Ala

405

410

415

- 60 -

Met Gly Ser Asp Ser Gln Ser Val Ser Ser Ser Thr Gln Asp Pro  
420 425 430

His Arg Gly Arg Gln Thr Leu Gly Ser Leu Arg Gly Leu Ala Lys Ala  
435 440 445

Lys Pro Glu Ala Ser Phe Gln Val Trp Asn Lys Asp Ser Ser Ser Lys  
450 455 460

Asn Leu Ile Pro Arg Leu Gln Lys Ile Trp Lys Asn Tyr Leu Ser Met  
465 470 475 480

Asn Lys Tyr Lys Val Ser Tyr Lys Gly Pro Gly Pro Gly Ile Lys Phe  
485 490 495

Ser Ala Glu Ala Leu Arg Cys His Leu Arg Asp His Val Asn Val Ser  
500 505 510

Met Val Glu Val Thr Asp Phe Pro Phe Asn Thr Ser Glu Trp Glu Gly  
515 520 525

Tyr Leu Pro Lys Glu Ser Ile Arg Thr Lys Ala Gly Pro Trp Gly Arg  
530 535 540

Cys Ala Val Val Ser Ser Ala Gly Ser Leu Lys Ser Ser Gln Leu Gly  
545 550 555 560

Arg Glu Ile Asp Asp His Asp Ala Val Leu Arg Phe Asn Gly Ala Pro  
565 570 575

Thr Ala Asn Phe Gln Gln Asp Val Gly Thr Lys Thr Thr Ile Arg Leu  
580 585 590

Met Asn Ser Gln Leu Val Thr Thr Glu Lys Arg Phe Leu Lys Asp Ser  
595 600 605

- 61 -

Leu Tyr Asn Glu Gly Ile Leu Ile Val Trp Asp Pro Ser Val Tyr His  
610 615 620

Ser Asp Ile Pro Lys Trp Tyr Gln Asn Pro Asp Tyr Asn Phe Phe Asn  
625 630 635 640

Asn Tyr Lys Thr Tyr Arg Lys Leu His Pro Asn Gln Pro Phe Tyr Ile  
645 650 655

Leu Lys Pro Gln Met Pro Trp Glu Leu Trp Asp Ile Leu Gln Glu Ile  
660 665 670

Ser Pro Glu Glu Ile Gln Pro Asn Pro Pro Ser Ser Gly Met Leu Gly  
675 680 685

Ile Ile Ile Met Met Thr Leu Cys Asp Gln Val Asp Ile Tyr Glu Phe  
690 695 700

Leu Pro Ser Lys Arg Lys Thr Asp Val Cys Tyr Tyr Tyr Gln Lys Phe  
705 710 715 720

Phe Asp Ser Ala Cys Thr Met Gly Ala Tyr His Pro Leu Leu Tyr Glu  
725 730 735

Lys Asn Leu Val Lys His Leu Asn Gln Gly Thr Asp Glu Asp Ile Tyr  
740 745 750

Leu Leu Gly Lys Ala Thr Leu Pro Gly Phe Arg Thr Ile His Cys  
755 760 765

Claims:

1. A protein having glycosyltransferase activity comprising identical or different catalytically active domains of glycosyltransferases.
2. A protein according to claim 1 which is a hybrid protein.
3. A protein according to claim 2 comprising a membrane-bound or soluble glycosyltransferase linked to a soluble glycosyltransferase.
4. A protein according to claim 2 comprising a suitable linker consisting of genetically encoded amino acids.
5. A protein according to claim 2 selected from the group consisting of the protein having the amino acid sequence depicted in SEQ ID NO. 5 and the protein having the amino acid sequence depicted in SEQ ID NO. 7.
6. A method for preparing a protein according to claim 2 comprising culturing a suitable transformed yeast strain under conditions which allow the expression of said protein.
7. A DNA molecule coding for a protein according to claim 2.
8. A hybrid vector comprising a DNA molecule according to claim 7.
9. A transformed yeast strain comprising a hybrid vector according to claim 8.
10. Use of a protein according to claim 1 for glycosylation.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 93/03194A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 C12N15/54 C12N15/62 C12N15/10 C12N15/63 C12N9/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY vol. 23, no. 7/8 , 1991 pages 695 - 702 SUNIL K. CAHTTERJEE 'Molecular cloning of human beta 1,4-galactosyltransferase and expression of the catalytic activity of the fusion protein in Escherichia coli' see page 695, right column, paragraph 2 see page 697, right column, paragraph 1 - page 698, right column, paragraph 4 ---</p> <p style="text-align: center;">-/-</p>	1,2,6,7

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

5 April 1994

Date of mailing of the international search report

04.05.94

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentstaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Montero Lopez, B

## INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/EP 93/03194

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO,A,91 06635 (REGENTS OF THE UNIVERSITY OF CALIFORNIA) 16 May 1991  cited in the application  see page 2, paragraph 3 - page 3,  paragraph 3  see page 8, paragraph 2  see page 11, paragraph 2 - page 12,  paragraph 1  see page 13, paragraph 3  see page 15, paragraph 3 - page 16,  paragraph 1</p> <p>-----</p>	1,6-10

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/EP 93/03194

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9106635	16-05-91	US-A-	5032519	16-07-91
		AU-B-	646233	17-02-94
		AU-A-	6648090	31-05-91
		EP-A-	0497878	12-08-92
		JP-T-	5504678	22-07-93